Page last updated: 2024-08-24

gemcitabine and Breast Cancer

gemcitabine has been researched along with Breast Cancer in 565 studies

Research

Studies (565)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	23 (4.07)	18.2507
2000's	276 (48.85)	29.6817
2010's	227 (40.18)	24.3611
2020's	39 (6.90)	2.80

Authors

Authors	Studies
Anderes, K; Blasina, A; Chen, E; Chen, P; Deng, Y; Grant, S; Hu, Q; Johnson, MD; Kania, RS; Kornmann, J; Lundgren, K; Ninkovic, S; Peng, Z; Register, J; Rogers, C; Teng, M; Zhu, J	1
Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E	1
Assaf, C; Blazejak, C; Gambichler, T; Gosman, J; Klemke, CD; Nicolay, JP; Olk, J; Stadler, R; Stendel, S; Stranzenbach, R; Wehkamp, U; Weyermann, M; Wobser, M	1
Fan, D; Fang, J; Feng, C; He, L; Liang, W; Qin, X; Wang, Q	1
Chen, D; Chen, F; Dong, L; Liu, D; Long, J; Wan, F; Wang, Y	1
Deng, L; Deng, Q; He, X; Lei, QY; Liu, C; Liu, S; Liu, Y; Lv, J; Qiang, J; Shao, ZM; Wang, D; Xia, J; Yu, Z; Zhang, L; Zhang, XY; Zhao, B; Zhou, L	1
Gao, Y; Maharjan, S; Mitragotri, S; Pan, DC; Singh, B; Zhang, YS; Zhao, Z	1
Banerjee, N; Basu, S; Bhattacharya, R; Chatterjee, K; Chattopadhyay, S; Choudhury, P; Mukhopadhyay, A; Mukhopadhyay, S; Nandi, SK; Roychowdhury, T; Saha, P	1
Bryant, HE; Bucklain, FA; Ciani, B; Ginn, L; Grant, E; Laity, P	1
Behera, C; Behl, A; Chhillar, AK; Datta, TK; Gupta, PN; Kumar, S; Mintoo, MJ; Sarwalia, P	1
Andugulapati, SB; Bhargava, SK; Ganthala, PD; Kulhari, H; Pooja, D; Sistla, R; Tunki, L	1
Arjyal, L; Khan, AM; Shamaileh, L; Simon, M	1
Tian, T	1
Liu, D; Ngo, L; Tsao, SC; Wang, Y; Zhang, W	1
Haltmair, G; Hatzichristodoulou, G; Heller, V; Pyrgidis, N; Sokolakis, I	1
Doğan, M; Kurtuluş, A; Özdemir, M; Türkel, A	1
Chae, YS; Im, SA; Jung, KH; Kim, JH; Kim, JY; Kim, TY; Lee, E; Lee, KS; Park, K; Park, YH; Sohn, J	1
Choi, JS; Doh, KO; Joshi, M; Park, JW	1
Dang, CT; DeFusco, P; Fornier, MN; Goldfarb, S; Gucalp, A; Hudis, CA; Iyengar, NM; Jhaveri, K; Jochelson, M; Lake, D; Modi, S; Norton, L; Patil, S; Singh, JC; Smyth, LM; Traina, TA; Troso-Sandoval, T; Ulaner, GA	1
Bi, PD; Duan, WJ; Liu, NQ; Ma, Y; Zhen, X	1
Chang, J; Chen, T; He, M; Hong, W; Li, F; Li, H; Li, J; Liu, L; Luo, D; Ran, L; Shan, L; Song, Y; Wang, B; Wang, H	1
Chen, T; Jin, Y; Xiao, Z; Zhuang, B	1
Cai, W; Chen, B; Geng, C; Jiang, L; Lu, H; Sun, J; Yang, B; Zhou, Y	1
Bender, L; Gantzer, J; Kurtz, JE; Somme, F; Weingertner, N	1
Debnath, MC; Ganguly, S; Kazi, J; Mukhopadhyay, R; Paul, B; Sen, R	1
Bartlett, DW; Desai, D; Guerrero, YA; Kindt, E; Maurer, TS; Solomon, DE; Spilker, ME; Sullivan, C	1
Griffin, JI; Ho, RJY; McConnachie, LA; Mu, Q; Wu, Y; Yu, J; Zhu, L	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Bottinor, W; Das, S; Nunnery, S	1
Aceti, M; Bayle, S; Duckett, D; Frydman, SM; Grant, W; McDonald, P; Monastyrskyi, A; Nieto, A; Quereda, V; Roush, WR; Sansil, SS; Teng, M; Vena, F	1
Casey, PJ; Chai, TF; Manu, KA; Wang, M	1
Amini, M; Arefian, E; Atyabi, F; Dinarvand, R; Norouzi, P; Seyedjafari, E	1
Chatterjee, D; Hauser, R; Kaufman, PA; Kazmi, S; Raju, D	1
Griffin, JI; Ho, RJ; McConnachie, LA; Mu, Q; Perazzolo, S; Shen, DD; Yu, J; Zhu, L	1
Andergassen, U; Bauer, E; Beckmann, MW; Bekes, I; Blohmer, JU; Brucker, SY; de Gregorio, A; de Gregorio, N; Deniz, M; Fasching, PA; Fehm, TN; Fink, V; Forstbauer, H; Friedl, TWP; Häberle, L; Heinrich, G; Janni, W; Lato, K; Lorenz, R; Mahner, S; Müller, V; Rack, B; Schneeweiss, A; Schrader, I; Tesch, H	1
Alcaraz-Sanabria, A; Burgos, M; Corrales-Sanchez, V; Galan-Moya, EM; Martinez-Canales, S; Montero, JC; Nieto-Jimenez, C; Nuncia-Cantarero, M; Ocaña, A; Pandiella, A	1
Dehghanian, A; Firouzabadi, D; Mahmoudi, L; Rezvani, A; Talei, A	1
Funakoshi, S; Hirose, S; Kouno, T; Machino, C; Oikawa, H; Sato, T	1
Goodwin, A; Im, SA; Kim, SB; Lanzalone, S; Lee, KH; Sohn, J; Usari, T	1
Adachi, S; Chishima, T; Doi, T; Endo, I; Hasegawa, S; Ichikawa, Y; Ishikawa, T; Kito, A; Morita, S; Morita, T; Narui, K; Oba, M; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A; Yamamoto, S	1
Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS	1
Asleh, K; Balslev, E; Gao, D; Jensen, MB; Leung, S; Lænkholm, AV; Nielsen, D; Nielsen, LB; Nielsen, TO; Riaz, N; Stovgaard, ES	1
Babu, D; Gautam, M; Karuppaiah, A; Natrajan, T; Nesamony, J; Rajan, R; Ranganathan, H; Sankar, V; Selvaraj, D; Siram, K	1
Guleria, A; Jain, P; Jangid, AK; Kulhari, H; Patel, K; Patel, S; Pooja, D	1
Ahn, JH; Chae, YS; Cho, EH; Im, SA; Jang, JH; Jung, KH; Kim, JH; Kim, JY; Lee, KH; Lee, KS; Lee, SY; Park, MS; Park, YH; Sohn, J	1
Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C	1
Cinar Ciftci, G; Guler, MO; Hamsici, S; Sardan Ekiz, M; Tekinay, AB	1
Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ	1
Aono, T; Masuda, N; Matsunami, N; Mizutani, M; Nakayama, T; Nishida, Y; Ooe, A; Tanaka, S; Tanino, H; Tokunaga, S; Tsurutani, J; Tsuyuki, S; Yamaguchi, M; Yamamoto, D; Yamamura, J; Yasojima, H; Yoshidome, K	1
Buchy, E; Cayre, F; Couvreur, P; Desmaële, D; Garcia-Argote, S; Mura, S; Pieters, G; Rouquette, M; Sobot, D; Vukosavljevic, B; Windbergs, M	1
Agostoni, V; Couvreur, P; Gref, R; Lampropoulou, M; Lazarou, YG; Maksimenko, A; Rodriguez-Ruiz, V; Salzano, G; Yannakopoulou, K	1
Jhaj, G; Jhaj, R; Shrier, EM	1
Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, YH; Sohn, JH	1
Jensen, AB; Knoop, A; Langkjer, ST; Rosvig, LH	1
Di, GH; Hong, Q; Kuang, XY; Shao, ZM; Yang, L; Yu, SJ	1
Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H	1
Arun, B; Buzdar, AU; Hortobagyi, GN; Moulder, SL; Murray, JL; Murthy, RK; Shroff, GS; Stalzer, CJ; Szklaruk, J; Valero, V; Yam, C; Yang, W	1
Jiang, L; Lee, SC; Ng, TC	1
Fuse, T; Ozeki, T; Tagami, T; Tane, M	1
Beijnen, JH; Derissen, EJB; Huitema, ADR; Rosing, H; Schellens, JHM	1
Balmaña, J; Cedrés, S; Cruz, C; Felip, E; Llop-Guevara, A; Mancuso, F; Martinez de Castro, A; Martinez-Marti, A; Miquel, JM; Navarro, A; Nuciforo, P; Pardo, N; Remon, J; Sansano, I; Serra, V; Vivancos, A; Zeron-Medina, J	1
Chen, G; Huang, Y; Lu, W; Svirskis, D; Wen, J; Ying, M	1
Bhatnagar, S; Kumari, P; Pattarabhiran, SP; Venuganti, VVK	1
Dora, CP; Gupta, RC; Jain, S; Katiyar, SS; Kumar Agrawal, A; Kushwah, V; Lamprou, DA	1
Agrawal, AK; Gupta, RC; Jain, S; Katiyar, SS; Kushwah, V	1
Hasanov, M; Hernandez, CMR; Konoplev, SN	1
Couvreur, P; Denis, S; Guillaneuf, Y; Jacobs, M; Mougin, J; Mura, S; Nicolas, J; Vinciguerra, D	1
Goto, R; Hattori, M; Iwata, H; Kashiwaba, M; Kondo, N	1
Martins, A; Neves, NM; Oliveira, C; Reis, RL; Silva, TH	1
Chavez-MacGregor, M; Giordano, SH; Kehl, KL; Niu, J	1
Fu, J; Jin, Y; Li, X; Liang, X; Luo, Y; Zhang, J; Zhang, P; Zou, Q	1
Asleh, K; Balslev, E; Burugu, S; Ejlertsen, B; Gao, D; Jensen, MB; Laenkholm, AV; Lyck Carstensen, S; Nielsen, DL; Nielsen, TO; Tykjaer Jørgensen, CL; Won, JR	1
Couvreur, P; Denis, S; Guillaneuf, Y; Jacobs, M; Lazzari, G; Mougin, J; Mura, S; Nicolas, J; Vinciguerra, D; Zhu, C	1
Le Tourneau, C; Ricci, F	1
Bekes, I; Cámara, RJA; Deniz, M; Fink, V; Friedl, TWP; Janni, W; Lato, K; Rack, B; Schwentner, L; Singer, S; Widschwendter, P	1
Ali, M; Batool, F; Fatima, M; Iqbal Ahmed, MM; Munch-Petersen, B; Mutahir, Z; Riaz, A	1
Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, S; Park, YH; Sohn, J	1
Baikoghli, M; Borowsky, AD; Cheng, RH; Ferrara, KW; Foiret, J; Hubbard, NE; Ingham, ES; Kheirolomoom, A; Mahakian, LM; Tam, SM; Tucci, ST	1
Grafmüller, A; Hall, CK; Lilova, RL; Menegatti, S; Schneible, JD; Singhal, A	1
Bang, YJ; Han, SW; Im, SA; Kim, HJ; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Oh, DY; Yoon, YK	1
Budman, DR; Calabro, A; Lesser, M; Rosen, L	1
Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W	1
Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M	1
Angspatt, A; Sriussadaporn, S	1
Amadori, D; Bauknecht, T; Carrasco, E; Desaiah, D; Labianca, R; Martin, M; Moreau, V; Roesel, S; Soldatenkova, V; Uziely, B	1
Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH	1
Akewanlop, C; Ithimakin, S; O-Charoenrat, P; Prasarttong-Osoth, P; Ratanawichitrasin, A; Rojananin, S; Soparattanapaisarn, N; Srimuninnimit, V; Veerasarn, V	1
Singer, A; Tresley, J; Velazquez-Vega, J; Yepes, M	1
Fujita, S; Katagata, N; Matsuzaki, M; Nomizu, T; Saito, M; Sakuma, T; Takenoshita, S; Watanabe, F	1
Akyol, M; Alacacioglu, A; Bayoglu, V; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Somali, I; Tarhan, MO	1
Li, WB; Li, YY; Qin, YZ; Qu, XJ; Wang, RQ	1
Li, W; Li, X; Wang, H	1
Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL	1
Inaba, M; Kojima, I; Matsuura, H; Matsuzu, K; Mukaibashi, T; Nakayama, H; Nishiyama, S; Shimizu, S; Yamanaka, A; Yamanaka, T; Yoshida, A	1
Eichler, K; Gruber-Rouh, T; Hammerstingl, R; Jakobi, S; Vogl, TJ; Zangos, S	1
Daignault, S; Healy, P; O'Malley, M; Ramnath, N	1
Balasubramanian, SU; Harfouche, R; Luchette, M; Papa, AL; Sarangi, S; Sengupta, S; Sidiqui, A	1
Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P	1
Aogi, K; Hara, F; Kiyoto, S; Ohsumi, S; Takabatake, D; Takahashi, M; Takashima, S; Watanabe, M	1
Chi, HD; Liu, Z; Orlando, M; Quinlivan, M; Xu, B; Zhang, XQ	1
Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Nielsen, DL; Nielsen, KV	1
Hattori, M; Iwata, H; Kaise, H; Kawaguchi Ushio, A; Kohno, N	1
Anota, A; Auquier, P; Bascoul-Mollevi, C; Bonnetain, F; Borg, C; Chibaudel, B; Fiteni, F; Hamidou, Z; Paget-Bailly, S; Westeel, V	1
Begum, S; Harish, G; Hussain, A; Javed, E; Khan, MA; Mohsin, J; Nusri, Qel-A; Prabhu, SA; Sharma, C	1
Carafa, M; Celia, C; Cilurzo, F; Di Marzio, L; Gentile, E; Paolino, D; Ventura, CA; Wolfram, J	1
Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Liu, S; Nielsen, DL; Nielsen, TO; Wallden, B	1
Abraham, J; Caldas, C; Chan, S; Dean, S; Dunn, J; Earl, HM; Fenwick, N; Gallagher, C; Gounaris, I; Harries, M; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; Iddawela, M; Laing, R; McAdam, K; Provenzano, E; Ritchie, D; Skene, A; Vallier, AL; Wishart, G; Young, J	1
Ahn, JS; Chang, W; Choi, MK; Im, SA; Im, YH; Kim, S; Lee, SY; Park, YH; Woo, SY	1
Abdi, E; Badger, HD; Boyle, F; Bull, J; Chirgwin, J; Forbes, JF; Francis, PA; Gebski, V; Kannourakis, G; Leong, E; Lindsay, DF; McCarthy, N; Reaby, L; Simpson, A; Veillard, AS; Wilcken, N; Zannino, D; Zdenkowski, N	1
Jinno, H; Kitagawa, Y; Kitasato, K; Murai, S; Nakadai, J; Oto, I; Shimizu, H; Yabe, N; Yoshikawa, T	1
Driessen, W; Jiang, X; Wu, W	1
Beegle, N; Blau, S; Cox, D; Dranitsaris, G; Faria, C; Kalberer, T	1
Balzarini, J; Fieuws, S; Hofer, A; Liekens, S; Noppen, S; Ranjbarian, F; Sabuncuoğlu, S; Vande Voorde, J	1
Chan, S; Seidman, AD; Wang, J; Xu, B; Xu, C; Zhu, C	1
Barni, S; Blasi, L; Cinieri, S; Colucci, G; De Vita, F; Fedele, P; Filippelli, G; Gebbia, N; Giotta, F; Lorusso, V; Maiello, E; Orlando, L; Pappagallo, GL; Pisconti, S; Riccardi, F; Verderame, F	1
Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H	1
Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T	1
Balslev, E; Bartels, A; Bjerre, C; Bjerre, KD; Brünner, N; Ejlertsen, B; Jørgensen, CL; Nielsen, DL	1
Cao, J; Chen, H; Chen, WR; Fida, G; Gu, Y; Li, S; Qian, Z; Qin, J; Tian, C; Wang, Z	1
Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI	1
Baena, JM; Bayo, J; Blancas, I; Casal, J; Ciruelos, E; de la Haba, J; de Villena, MC; Galan, A; Gil, M; Jaen, A; Jara, C; Manso, L; Mel, JR; Murias, A; Salvador, J; Sanchez Rvira, P	1
Baay, M; Burrows, N; Deschoolmeester, V; Lardon, F; Laukens, K; Meijnders, P; Pauwels, B; Pauwels, P; Peeters, M; Van den Weyngaert, D; Van Gestel, D; Vermorken, JB; Vu, TN; Williams, KJ; Wouters, A	1
Chilakapati, DR; Chilakapati, SR; Kanala, JR; Manikonda, PK; Serasanambati, M	1
Hu, W; Jiang, YH; Ma, N; Sui, CG; Zheng, RR	1
Azim, HA; de Azambuja, E; Piccart, M; Sonnenblick, A	1
Agelaki, S; Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Vamvakas, L; Vardakis, N	1
Chowdhury, EH; Mozar, FS	1
Lan, H; Li, Y; Lin, CY	1
Cao, ZG; Chen, DN; Chen, L; Hu, X; Li, S; Ling, H; Qiao, F; Shao, ZM; Song, CG; Xia, C; Yao, L; Ye, FG	1
Aittomäki, K; Andrulis, IL; Blomqvist, C; Chang-Claude, J; Chenevix-Trench, G; Couch, FJ; Czene, K; Easton, DF; Eccles, D; Fagerholm, R; Fasching, PA; Figueroa, J; García-Closas, M; Greco, D; Hall, P; Hamann, U; Heikkinen, T; Hooning, MJ; Hopper, JL; Jager, A; Janni, W; Kabisch, M; Kataja, V; Keeman, R; Khan, S; Knight, JA; Lambrechts, D; Lindblom, A; Liu, J; Loehberg, CR; Luben, R; Mannermaa, A; Margolin, S; Muranen, TA; Nevanlinna, H; Olson, JE; Perkins, BJ; Pharoah, PD; Rafiq, S; Schmidt, MK; Seibold, P; Shah, M; Southey, MC; Tapper, W; Weinshilboum, R; Wildiers, H	1
Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP	1
Hayashi, K; Homma, S; Ishidao, T; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M	1
Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Jung, SH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH; Woo, SY	1
Li, H; Li, J; Sun, W; Wang, X; Wei, H; Yi, Z	1
Chen, B; He, A; Tang, M; Wang, W; Zheng, X; Zu, C	1
Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA	1
Dai, Y; Ishibashi, O; Kondo, T; Maeda, M; Ohkohchi, N; Watanabe, M	1
Hua, M; Ji, S; Li, L; Lu, W; Ren, Y; Wang, L; Yuan, Y; Zhou, S; Zhou, T; Zhou, X	1
Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN	1
Baranova, K; Carcangiu, ML; Dorman, SN; Knoll, JH; Mariani, G; Rogan, PK; Urquhart, BL	1
Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M	1
Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ	1
Hu, XC; Li, T; Ni, C; Tao, ZH; Wu, ZH; Xie, J; Zhang, J; Zhang, JF	1
Ahmadloo, N; Askarian, M; Hatam, N; Javan-Noghabi, J; Mohammadianpanah, M	1
Desco, M; Hernández-Agudo, E; Hidalgo, M; Lopez-Casas, PP; Megías, D; Mondejar, T; Mouron, S; Mulero, F; Quintela-Fandino, M; Sanchez, J; Soto-Montenegro, ML	1
Kim, JS; Koo, MJ; Shin, DH	1
Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A	1
Cao, L; Chen, L; Hu, X; Liu, M; Yao, G; Ye, C	1
Hu, XC; Li, T; Tao, ZH; Wu, ZH; Xie, J; Zhang, J; Zhang, JF; Zhao, J	1
Bowman, L; John, W; Liepa, AM; Melemed, A; Peterson, P; Shen, W; Smyth, EN	1
Han, NK; Jang, CY; Kim, JS; Shin, DH; Weon, KY	1
Chen, K; Lin, W; Liu, J; Tong, J; Ye, H; Zhang, C; Zhao, J; Zhu, W	1
Aroldi, F; Bertocchi, P; Fraccon, AP; Mutti, S; Prochilo, T; Rizzi, A; Savelli, G; Zaniboni, A	1
Doihara, H; Iwamoto, T; Matsuoka, J; Mitsuhashi, T; Mizoo, T; Motoki, T; Nogami, T; Ogasawara, Y; Shien, T; Taira, N; Tsuji, H; Yoshitomi, S	1
Leone, JP	1
Carrasco, N; De, A; Do, J; Foster, D; Jeffrey, SS; Renier, C; Reyna-Neyra, A; Tse, V; Vogel, H; Wapnir, I	1
Anamalai, M; Julka, PK; Kumaran, D; Nambirajan, A; Velu, U	1
Chen, L; Chen, M; Dai, F; He, M; Pan, T; Shen, P; Song, Y; Wan, X; Wang, Q; Xiao, P	1
Chen, YM; Fu, PF; Liu, Y; Lv, KZ; Wei, HY	1
Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC	1
Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E	1
Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G	1
Lian, B; Mo, Q; Qin, Q; Tan, Q; Wei, C; Yang, W	1
Chen, Y; He, Q; Zhang, H	1
Blackwood, E; Cao, Y; Evangelista, M; Klijn, C; Lee, HJ; Pham, V; Settleman, J; Stokoe, D; Wilson, C	1
Fasching, PA; Heinemann, V; Kalischefski, B; Kolbl, H; Laessig, D; Maubach, P; Meerpohl, H; Melchert, F; Morack, G; Scharl, A; Stauch, M; Stemmler, HJ; Vehling-Kaiser, U; Weber, B	1
Asmar, L; Boehm, KA; Doane, L; Loesch, D; McIntyre, K; Monticelli, M; O'Shaughnessy, JA; Orlando, M; Paul, D; Vaughn, LG; Vukelja, S; Zhan, F	1
Ansari, R; Geyer, CE; Hamm, JT; Kardinal, CG; Kim, W; Lembersky, BC; Paik, S; Rastogi, P; Raymond, JM; Robidoux, A; Shalaby, IA; Song, YK; Tseng, GC; Wilson, JW; Wolmark, N	1
Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM	1
Albain, KS; Calderillo-Ruiz, G; Jordaan, JP; Llombart, AC; Melemed, AS; Nag, SM; O'Shaughnessy, J; Pluzanska, A; Reyes-Vidal, JM; Rolski, J; Sekhon, JS; Simms, L	1
Brooks, KJ; Coleman, EJ; Vitetta, ES	1
Benezra, R; Bertolini, F; Colleoni, M; Daenen, LG; Emmenegger, U; Henke, E; Kerbel, RS; Langenberg, MH; Man, S; Mancuso, P; Roodhart, JM; Shaked, Y; Strieter, RM; Tang, T; Voest, EE; Witte, L; Xu, P; Zhu, Z	1
Fabi, A; Metro, G; Mottolese, M	1
Choi, J; Gump, J; Lacevic, M; Lee, JH; Lush, R; Minton, S; Moulder, S; Munster, P; Neuger, A; Sullivan, D; Valkov, N	1
Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K	1
Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N	1
Galmarini, CM; Kohli, E; Mitin, A; Vinogradov, SV; Warren, G; Zeman, A	1
Adrover, E; Calvo, L; Colomer, R; De la Haba, J; Del Barco, S; Rifà, J; Sánchez, P; Tusquets, I; Virizuela, JA	1
Blitzer, J; Evans, S; Flam, M; Hager, S; Link, J; Lyons, W; Nagourney, RA; Sommers, BL	1
Barton, JH; Burris, HA; Drosick, D; Greco, FA; Hainsworth, JD; Shipley, D; Simons, L; Spigel, DR; Yardley, DA	1
Cardenal Escarcena, A; Fernández Sarabia, MT; García Bernardo, L; Rodríguez García, JM; Serrano Vicente, J	1
Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP; Salanti, G	1
Bane, CL; Gross, GG; LaPlant, BR; Palmieri, FM; Roy, V	1
Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Kalbakis, K; Kalykaki, A; Mavroudis, D; Vamvakas, L	1
Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, ES; Lee, KS; Nam, BH; Ro, J; Shin, KH	1
Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT	1
Albain, KS; Bayer, R; Chew, HK; Doroshow, JH; Frankel, P; Gandara, DR; Gordon, M; Hantel, A; Lenz, HJ; Margolin, KA; Russell, C; Somlo, G; Spicer, D; Stiff, PJ; Synold, T; Tetef, ML; Yang, D; Zhang, W	1
Alacacioglu, A; Erten, C; Meydan, N; Somali, I; Tarhan, MO; Usalp, S; Yilmaz, U	1
Chen, DD; Li, WY; Lu, XM; Shu, XG; Tao, KX; Tong, Q; Wang, GB	1
Elzawawy, A	1
Brandi, M; Colucci, G; Corsetti, S; DI Lauro, L; Fattoruso, SI; Foggi, P; Gebbia, V; Giannarelli, D; Giotta, F; Lopez, M; Lorusso, V; Sergi, D; Vici, P; Viola, G; Vitucci, C	1
Estephan, F; Esteva, FJ; Frye, DK; Ibrahim, NK; Mejia, JA; Valero, V	1
Kim, SN; Lee, KS; Nam, BH; Park, IH; Ro, J; Yun, YH	1
Alvarado-Miranda, A; Arrieta, O; Bargallo-Rocha, E; Gamboa-Vignolle, C; Lara-Medina, F; Morales-Barrera, R; Perez-Sanchez, V; Ramirez-Ugalde, T; Saavedra-Perez, D; Zinser-Sierra, J	1
Canil, C; Dent, SF; Gertler, S; Goel, R; Iscoe, N; Keller, O; Segal, R; Verma, S; Young, V	1
Eichler, K; Gruber-Rouh, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S	1
Barton, J; Burris, HA; Greco, FA; Hainsworth, JD; Hanson, S; Spigel, DR; Yardley, DA	1
Chan, D; Chuah, B; Goh, BC; Lee, SC; Lim, SE; Soo, R; Tan, SH; Tiemsim Cordero, M; Wong, CI; Yeo, WL	1
Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F	1
Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC	1
Aogi, K; Fujiwara, Y; Iwata, H; Nambu, Y; Saeki, T; Saji, S; Sasaki, Y; Suri, A; Suzuki, Y; Takashima, S; Tokuda, Y	1
Armesilla, AL; Brown, J; Darling, JL; Goessl, E; Guo, X; Pandey, S; Wang, W; Xu, B	1
Ekerbicer, N; Inan, S; Karakaya, J; Muftuoglu, SF; Vatansever, HS; Zeybek, ND	1
Clegg, A; Cooper, K; Jones, J; Loveman, E; Takeda, A; Tan, SC	1
Gore, EM; Jones, BS; Marques, MB	1
Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T	1
Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R	1
Puglisi, F	1
Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C	1
Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR	1
Antoniani, B; Bepler, G; Boulware, D; Cognetti, F; Fabi, A; Lara Rivera, S; Metro, G; Monteiro, AN; Mottolese, M; Schell, M; Vici, P; Zheng, Z	1
Gupta, S; Mallik, S; Munshi, A	1
Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y	1
Burton, GV; Koshy, N; Mansour, R; Quispe, D; Shi, R	1
Abdelhamid, T; El-Mesidi, S; Elzawhri, H; Goda, Y; Kandeel, A; Koheil, H; Meshref, M; Saad, E; Shehata, S; Zaki, M	1
Hall, PD; Teusink, AC	1
Elias, AD; Gralow, J; Muscato, J; Neubauer, M; O'Shaughnessy, JA; Orlando, M; Pippen, J; Shonukan, O; Stokoe, C; Vaughn, LG; Wang, Y	1
Edina, M; László, L; Tamás, N	1
Dumontet, C; Hage-Sleiman, R; Herveau, S; Laurier, JF; Matera, EL	2
Ardavanis, A; Arnogiannaki, N; Doufexis, D; Kountourakis, P; Maliou, S; Missitzis, I; Pissakas, G; Sotiropoulou, A; Zobolas, V	1
Dickson, NR; Foust, JT; Grapski, R; Hainsworth, JD; Hendricks, LK; Peacock, NW; Scott, WL; Vázquez, ER; White, MB; Yardley, DA	1
Bepler, G; Cognetti, F; Conti, F; Di Lauro, L; Fabi, A; Giannarelli, D; Lopez, M; Metro, G; Sergi, D; Tomao, F; Vici, P	1
Baez, O; Castrellon, A; Ferrell, A; Glück, S; Higgins, C; Hurley, E; Hurley, J; Lobo, C; Lopes, G; Reis, I; Richman, S; Seo, P; Silva, O; Slingerland, J; Tukia, K; Welsh, C	1
Aogi, K; Fujimoto, T; Funai, J; Kamigaki, S; Okazaki, M; Saeki, T; Sagara, Y; Takashima, S; Toi, M; Yoshida, M	1
Burris, HA; Daniel, B; Hainsworth, JD; Inhorn, R; Lane, CM; Naot, Y; Vazquez, ER; Yardley, DA; Zubkus, J	1
Jiang, WG; Lane, J; Martin, TA; Mason, MD; McGuigan, C	1
Alli, E; Ford, JM; Hastak, K	1
Bult, P; van Herpen, CM; van Laarhoven, HW; Wesseling, P; Willemsen, AE	1
Huang, XE; Tang, JH; Xu, HX; Yao, CY	1
Dalgleish, AG; Gravett, AM; Liu, WM	1
Gupta, P; Khanna, AK; Khanna, R; Singh, S	1
Alberto, M; Alessandro, C; Artioli, G; Borgato, L; Bozza, F; Cappetta, A; Davide, P; Fernando, B; Giorgio, Z; Grazia, A; Lucia, B; Marchet, A; Mocellin, S; Pastorelli, D; Simone, M; Stefania, Z; Zavagno, G; Zovato, S	1
Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L	1
Guan, Z; Jiang, Z; Shen, Z; Xu, B; Zhang, X	1
Arenas, DR; Arvelo, F; Kouznetsov, VV; Muñoz, A; Sojo, F	1
Coyne, CP; Jones, T; Pharr, T	1
Abskharon, JE; Jost, A; Mack, MG; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S	1
Chen, SM; Chen, YY; Huang, CH; Li, SH; Rau, KM; Tang, Y; Wu, SC	1
de Lima Araújo, LH; Gomes, CA; Moitinho, MV; Noronha Júnior, H; Silva, AM	1
Bradley, C; Koo, IC; O'Shaughnessy, J; Osborne, C; Patt, D; Pippen, JE; Rocha, C; Sherman, BM; Yoffe, M	1
Jiang, Z; Lu, X; Shen, G; Song, S; Wang, T; Wu, S; Zeng, M; Zhang, S	1
Brito, LG; de Andrade, JM; Lins-Almeida, T; Marana, HR; Peria, FM; Pinheiro, MN; Tiezzi, DG; Zola, FE	1
Chaigneau, L; Chargari, C; Clavreul, G; Dumanoir, C; Jacquin, JP; Magné, N; Mélis, A; Merrouche, Y; Mille, D; Nourissat, A; Orfeuvre, H; Savary, J; Thorin, J	1
Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F	1
Halim, A; Wahba, H	1
Abenhardt, W; Brudler, O; Brugger, W; diGioia, D; Freier, W; Gitsch, G; Heinemann, V; Hurtz, HJ; Jonat, W; Kettner, E; Rösel, S; Stemmler, HJ; Tesch, H; Tessen, HW	1
Chung, HC; Del Giglio, A; Feng, J; Jiang, Z; Kim, SB; Malzyner, A; Pen, DL; Shen, LJ; Xu, B; Yu, S	1
Azzarello, D; Bottari, M; Maisano, M; Maisano, R; Nardi, M; Raffaele, M; Zavettieri, M	1
Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C	1
Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H	1
Bergerat, JP; Delpeuch, A; Leveque, D; Rob, L	1
Donders, AR; Oostendorp, LJ; Ottevanger, PB; Stalmeier, PF; van der Graaf, WT	1
Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S	1
Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L	1
Funai, J; Ishii, M; Saeki, T; Takao, S; Takashima, S; Tokuda, Y	1
Chen, H; Li, H; Li, W; Lu, X; Shu, X; Tong, Q; Wang, G	1
Abele, JT; El-Mabhouh, AA; McEwan, AJ; Mercer, JR; Nation, PN; Postema, E; Riauka, T	1
Filatova, LV; Gershanovich, ML; Latipova, DKh; Semiglazova, TIu	1
Albain, KS; Donaldson, GW; Liepa, AM; Melemed, AS; Moinpour, CM; O'Shaughnessy, J	1
Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I	1
Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH	1
Dees, EC	1
Andersson, M; Bjerre, KD; Cold, S; Jakobsen, EH; Jørgensen, CL; Kamby, C; Møller, S; Nielsen, DL; Stenbygaard, L; Sørensen, PG	1
Casale, F; Cilurzo, F; Cosco, D; Fresta, M; Paolino, D	1
Colucci, G; D'Amico, C; Di Lauro, L; Giannarelli, D; Giotta, F; Latorre, A; Mariani, L; Pizzuti, L; Sergi, D; Vici, P; Vizza, E	1
Ahn, JH; Ahn, JS; Ha, SW; Im, SA; Im, YH; Kang, HS; Kim, JH; Kim, SB; Kwon, Y; Lee, ES; Lee, KS; Noh, DY; Park, IA; Ro, J; Shin, KH	1
Brundage, RC; Hull, JM; Khatri, A; Kirstein, MN; Williams, BW; Yee, D	1
Alkis, N; Benekli, M; Berk, V; Bilici, A; Colak, D; Coskun, U; Dane, F; Dikilitas, M; Gumus, M; Kaplan, MA; Ozdemir, NY; Ozkan, M	1
Aydemir, I; Inan, S; Ozbilgin, K; Uluer, ET; Vatansever, HS	1
Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V	1
Moran, SL; Peethambaram, PP; Reynolds, C; Shon, W; Swapp, RE	1
Bordeleau, L; Kim, S; Seki, J; Sridhar, S; Tannock, I	1
Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA	1
Cui, Y; Dong, N; Guo, Q; Li, H; Wang, M	1
Georgoulias, V; Kalbakis, K; Karachaliou, N; Kouroussis, Ch; Mavroudis, D; Papakotoulas, P; Poppis, E; Tryfonidis, K; Vardakis, N	1
Chilelli, M; D'Auria, G; Fabbri, MA; Frittelli, P; Massari, A; Moscetti, L; Natoli, G; Nelli, F; Ruggeri, EM	1
Abou-Tarboush, FM; Al-Buhairi, M; Al-Harbi, N; Al-Qadasi, WD; Alhazza, I; Alsbeih, G; Farah, MA; Saeed, NM; Salem, SD	1
Barraclough, H; Chacko, RT; Dhindsa, N; Julka, PK; Koppiker, CB; Majumdar, A; Nag, S; Nair, A; Parshad, R; Puri, T; Seth, A; Xue, FC	1
DeMichele, A; Gogineni, K	1
Abdullah, M; Al Khodary, A; Barsoum, M; El Nowieam, S; El Zawahry, H; Gaafar, R; Gouda, Y; Halim, IA; Hamada, E; Hamid, TA; Kohail, H; Mansour, O; Meshref, M; Shehata, S; Taleb, FA; Wareth, AA	1
Aracil, M; Arguelaguet, E; Hernández-Losa, J; Jimeno, J; Marés, R; Pons, B; Ramón Y Cajal, S; Somoza, R; Teixidó, C	1
Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B	1
Adamo, B; Adamo, V; Agostino, RM; Caristi, N; Franchina, T; Proto, C; Ricciardi, GR	1
Gradishar, WJ	1
Aarts, M; Ashworth, A; Garcia-Murillas, I; Gevensleben, H; Hurd, MS; Sharpe, R; Shumway, SD; Toniatti, C; Turner, NC	1
Antón, A; Barnadas, A; Carrasco, E; Castellá, E; García-Andrade, C; Lomas, M; Palacios, JL; Ramírez, C; Ramírez, JL; Ríos, MJ; Rodríguez-Pinilla, M; San Antonio, B; Sánchez-Rovira, P; Velasco, A	1
Cavallaro, G; Celia, C; Fresta, M; Giammona, G; Licciardi, M; Paolino, D	1
Feng, Q; Gao, SY; Tao, XM; Wang, JB; Wang, JC; Zhang, LR; Zhang, Q	1
He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y	1
Bourgaux, C; Couvreur, P; Desmaële, D; Lepeltier, E; Lepêtre, S; Maksimenko, A; Mougin, J; Mura, S; Sliwinski, E; Zouhiri, F	1
Arrowsmith, E; Beck, T; Borson, R; Bromund, J; Hager, S; Harker, G; Harrer, G; Horvath, W; Jones, M; Kornberg, LJ; Kudrik, FJ; Malamud, SC; Obasaju, C; Orlando, M; Reeves, J; Tai, DF; Tillinghast, G; Yardley, DA; Zeigler, H	1
Alvarez, R; Aribi, A; Chan, KT; Doan, NB; Gery, S; Ho, Q; Koeffler, HP; Lee, DH; Lee, K; Said, JW; Thoennissen, GB; Thoennissen, NH; Toh, M	1
Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB	1
Kakimoto, M; Kawashima, H; Koshiishi, H; Miyamoto, H; Okamura, T	1
Bitterman, PB; Jacobson, B; Jia, Y; Kratzke, R; Li, S; McCauley, J; Wagner, CR	1
Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P	1
Blackhurst, DW; Gill, SE; Puls, LE; Shrum, KJ; Thompson, LK	1
Aigner, J; Jäger, D; Lorenzo Bermejo, J; Marmé, F; Schneeweiss, A; Sinn, P; Sohn, C	1
Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A	1
Perez, EA; Qu, G	1
Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP	1
Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ	1
Besse, B; Spano, JP	1
André, T; Culine, S; Epaud, C; Gligorov, J	1
Durgam, S; Levin, M; Novetsky, A	1
Adjei, AA	4
Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N	1
Accurso, V; Capaccetti, B; Cascinu, S; Catalano, V; Ferraù, F; Filippelli, G; Franciosi, V; Gasparini, G; Gattuso, D; Morabito, A; Palmeri, S; Scinto, F; Zagonel, V	1
Baay, MF; de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Vermorken, JB	1
Heinemann, V	4
Seidman, AD	4
Jassem, J	1
Fumoleau, P	1
Sledge, GW	2
O'shaughnessy, J	2
Chen, WR; Ishmael, DR; Liu, H; Nordquist, JA; Nordquist, RE	1
Casado, V; Dómine, M; Dorta, FJ; Estévez, LG; Florián, J; Jiménez, E; Léon, A; Lobo, F; Lomas, M; López, P; Virizuela, JA	1
Agelaki, S; Alexopoulos, A; Ardavanis, A; Georgoulias, V; Kalbakis, K; Karyda, E; Kouroussis, Ch; Malamos, N; Malas, K; Tselepatiotis, E	1
Amabile, G; D'Aiuto, G; de Matteis, A; Di Maio, M; Gridelli, C; Labonia, V; Landi, G; Nuzzo, F; Perrone, F; Rossi, E	1
Ardine, M; Bergnolo, P; Berruti, A; Bertetto, O; Coccorullo, Z; Comandone, A; Donadio, M; Fea, E; Mistrangelo, M; Ritorto, G	1
Ali, S; Aranha, O; Li, Y; Pettit, GR; Philip, PA; Sarkar, FH	1
Albain, KS; Cheng, C; Chiu, A; Doroshow, JH; Frankel, P; Gandara, D; Juhasz, A; Lenz, HJ; Longmate, J; Margolin, K; Newman, EM; Rivera, H; Synold, T; Vishwanath, R; Wilczynski, S; Yen, Y	1
Adinin, R; Arun, B; Hoelzer, K; Hortobagyi, GN; Pusztai, L; Rivera, E; Royce, M; Valero, V; Wade, JL; Walters, R	1
Lambiase, L; Li, J; Monteiro, C; Robinson, K; Schiff, M	1
Atadja, P; Bali, P; Bhalla, K; Donapaty, S; Fuino, L; Guo, F; Wang, HG; Wittmann, S; Yamaguchi, H	1
Amadori, D; Fabbri, M; Frassineti, GL; Ibrahim, T; Monti, M; Ricotti, L; Zoli, W	1
Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D	1
Andreola, G; Crucitta, E; D'Aprile, M; De Lena, M; Locopo, N; Lorusso, V; Marini, L; Silvestris, N	1
O'Shaughnessy, JA	1
Modi, S; Seidman, AD	1
Yardley, DA	4
Perez, EA	1
DeMichele, A; Domchek, S; Fox, K; Stein, S	1
Geyer, CE; Mamounas, EP; Swain, SM	1
Alonso, S; Barnadas, A; Carañana, V; Colomer, R; Fernández, Y; García-Conde, J; Guillem, V; Hornedo, J; Llombart-Cussac, A; Lluch, A; Montero, S; Ojeda, B	1
Seidman, A	1
Balbiani, L; Brosio, C; Caccia, G; Delfino, C; Flores Morales, D; Mickiewicz, E; Riva Gonzáles, L; Rodger, J; Zori Comba, A	1
Murad, AM	1
Zielinski, CC	2
Li, M; Rinehart, JJ; Wang, H; Zhang, R	1
Balbiani, L; Brosio, C; Caccia, G; Comba, AZ; Delfino, C; Gonzáles, LR; Mickiewicz, E; Morales, DF; Rodger, J	1
Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ	1
Im, MM; Ostruszka, L; Robinson, BW; Shewach, DS	1
Brandi, M; Colucci, G; Gebbia, N; Giotta, F; Lopez, M; Schittulli, F; Valerio, MR; Vici, P	1
Alexopoulos, A; Karamouzis, MV; Rigatos, G	1
Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martn-Richard, M; Mayordomo, JI; Pelegrí, A; Vázquez, S; Virizuela, J	1
Calvo, I; Casado, V; Daz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; Sánchez-Rovira, P	1
Miles, D; Reichardt, P	1
Chahine, GY; Dagher, JE; Farhat, FS; Ghosn, MG; Kattan, JG; Mokaddem, WT; Nasr, FL; Tueni, EA	1
Kimmel, G; Marsland, T; O'Shaughnessy, JA; Pippen, JE; Ratnam, S; Vukelja, S	1
Bengala, C; Campani, D; Collecchi, P; Conte, PF; Donati, S; Gennari, A; Guarneri, V; Maur, M; Orlandini, C	1
Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D	1
Airoldi, M; Cagliero, E; Cattel, L; Goffredo, F; Passera, R; Stella, B	1
Hobbs, KB; Kroll, DJ; Seewaldt, VL; Shaw, HS	1
Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D	1
Androulakis, N; Christophilakis, Ch; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Malamos, N; Mavroudis, D; Milaki, G; Polyzos, A; Varthalitis, I	1
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P	1
Aravantinos, G; Christodoulou, C; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Papakostas, P; Razis, E; Skarlos, D; Tsavdaridis, D	1
Blohmer, JU; Dieing, A; Eggemann, H; Elling, D; Heilmann, V; Krocker, J; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Sezer, O	1
Altinoz, MA; Bilir, A; Guneri, AD	1
Bilancia, D; Dinota, A; Manzione, L; Romano, R	1
Azria, D; Coelho, M; Culine, S; Dubois, JB; Larbouret, C; Lemanski, C; Pèlegrin, A; Serre, A; Ychou, M	1
Colomer, R	2
Li, HC; Russell, CA	1
Poole, C	1
Bastert, G; Hamerla, R; Huober, J; Lichter, P; Schneeweiss, A; Wallwiener, D	1
Konecny, GE; Pegram, MD	1
Argani, P; Brinker, DA; Haas, M; Montgomery, EA; Wu, J	1
Ali, S; Aranha, O; El-Rayes, BF; Philip, PA; Sarkar, FH	1
Burch, PA; Cannon, MW; Hillman, DW; Ingle, JN; Krook, JE; Mailliard, JA; Perez, EA; Rowland, KM; Veeder, MH	1
Advani, SH; Doval, DC; Ermisch, S; Feher, O; Jassem, J; Khoo, KS; Miller, MA; Morack, G; Roychowdhury, D; Vodvarka, P; von Minckwitz, G	1
Chung, HC; Jeung, HC; Kim, GE; Kim, YT; Moon, YH; Rha, SY; Roh, JK; Sohn, JH; Suh, CO; Yang, WI	1
Bach, AM; Choi, J; Currie, VE; D'Andrea, GM; Hudis, CA; Lake, DE; Moasser, MM; Modi, S; Norton, L; Panageas, KS; Seidman, AD; Theodoulou, M	1
Filatova, LV; Gershanovich, ML; Semiglazova, TIu	1
Czejka, M; Heinz, D; Muric, L; Ostermann, E; Schueller, J	1
Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A	1
Akrivakis, K; Flath, B; Heilmann, V; Kreienberg, R; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O	1
Cajozzo, M; Comella, G; Condemi, G; Danova, M; De Cataldis, G; Farris, A; Ferraù, F; Filippelli, G; Iannitto, E; Leonardi, V; Macaluso, MC; Mangiameli, A; Massidda, B; Misino, A; Palmeri, L; Palmeri, S; Spada, S; Vaglica, M	1
Dieing, A; Eggemann, H; Elling, D; Flath, B; Hauptmann, S; Heilmann, V; Jehn, C; Krocker, J; Kümmel, S; Lehenbauer-Dehm, S; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Wischnewsky, MB	1
Dieing, A; Flath, B; Heilmann, V; Jehn, C; Lehenbauer-Dehm, S; Possinger, K; Schmid, P; Schulz, CO; Sezer, O	1
Dumontet, C; Galmarini, CM; Guittet, O; Jordheim, LP; Lepoivre, M	1
Bhalla, KN; Swaby, RF	1
Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D	1
Bosse, D; Heinemann, V; Kahlert, S; Losem, C; Rauthe, G; Stemmler, HJ; Wohlrab, A	1
Carlini, P; Carpino, A; Cianciulli, AM; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Lorusso, V; Mottolese, M; Papaldo, P; Salesi, N; Sperduti, I	1
Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Saraydaroglu, O; Tasdelen, I; Tolunay, S; Topal, U	1
Arunabh, T; Davidoff, S; Shah, RD	1
Biroccio, A; D'Angelo, C; Leonetti, C; Lopez, M; Paoletti, G; Scarsella, M; Zupi, G	1
Moreno-Aspitia, A; Perez, EA	1
Adjei, AA; Fitch, TR; Hillman, DW; Ingle, JN; Kugler, JW; Ma, CX; Niedringhaus, RD; Perez, EA; Rowland, KM; Steen, P	1
Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N	1
Barnadas, A	1
Fumoleau, P; Levy, C	1
Beha, M; Brudler, O; Heinemann, V; Kahlert, S; Müller, S; Stauch, B; Stemmler, HJ	1
Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martín-Richard, M; Mayordomo, JI; Pelegrí, A; Vásquez, S; Virizuela, J	1
Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S	1
Perez, E; Wirk, B	1
Brundage, RC; Elmquist, WF; Guire, DE; Kirstein, MN; Marker, PH; Remmel, RP; Yee, D	1
Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B	1
Muss, HB; Perez, E	1
Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F	1
Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L	1
Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J	1
Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M	1
Booker, AJ; Christensen, LA; Finch, RA; Vasquez, KM	1
Benner, A; Brors, B; Eils, R; Hahn, M; Kramer, H; Lichter, P; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; Tews, B; Thuerigen, O; Toedt, G; Warnat, P	1
Budman, DR; Calabro, A	1
Czarnecki, A; Voss, S	1
Aguirre, G; Alexander, F; Avila, E; Calderillo, G; Fuentes, H; Gallardo, D; Oñate-Ocaña, LF; Otero, J; Perez, L; Ramirez, M	1
Choi, YH; Chung, HC; Jeung, HC; Jung, JJ; Kim, TS; Kwon, WS; Lee, JO; Park, KH; Rha, SY	1
Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S	1
Aravantinos, G; Bacoyiannis, H; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Koutras, A; Makatsoris, T; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E	1
Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P	1
Choi, CW; Kim, AR; Kim, BS; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Seo, JH; Shin, SW	1
Ito, Y; Tokudome, N	1
Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Sumitsawan, S; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K	1
Fan, Z; Glazer, RI; Li, X; Liang, K; Lu, Y; Mills, GB; Zeng, X	1
Smith, IE	1
Ferrazzi, E; Stievano, L	1
Amadori, D; Cecconetto, L	1
Morandi, P	1
Amici, S; Bonginelli, P; Bonsignori, M; Carillio, G; De Sio, L; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Massaccesi, C; Morabito, A; Torino, F	1
Fan, W; Kraft, AS; Sui, M; Xiong, X	1
Schultze, JL	1
Cecere, F; Cuello, M; Felip, E; Reguart, N; Rosell, R; Santarpia, M; Taron, M	1
Jackisch, C	1
Airoldi, M; Cattel, L; Delprino, L; Micari, C; Passera, R; Pedani, F	1
Basso, U; Brunello, A; De Salvo, GL; Fratino, L; Ghiotto, C; Koussis, H; Lonardi, S; Lumachi, F; Monfardini, S; Pasetto, LM	1
Antón, A; Cuevas, C; Hernández-Vargas, H; Julián-Tendero, M; Moreno-Bueno, G; Palacios, J; Ríos, MJ; Rodríguez-Pinilla, SM; Sánchez-Rovira, P	1
Bozec, L; Campone, M; Diéras, V; Espié, M; Fumoleau, P; Kayitalire, L; Petit, T; Pouillart, P; Pujade-Lauraine, E; Serin, D; Viens, P	1
Amarantidis, K; Christophillakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kalbakis, K; Malamos, N; Mavroudis, D; Mavrousis, D; Potamianou, A; Tselepatiotis, E; Vamvakas, L	1
Li, JH; Luo, XG	1
Ciruelos, E; Colomer, R; Cortés-Funes, H; Hornedo, J; Llombart-Cussac, A; Mayordomo, JI; Ojeda, B; Rifà, J; Tusquets, I; Vicente, D	1
Adrover, E; Balil, A; Calvo, L; Carrasco, E; Casado, A; Escudero, MJ; García-Mata, J; García-Saenz, JA; Guillem, V; Jara, C; Mahillo, E; Martín, M; Mel, JR; Morales-Vasquez, F; Muñoz, M; Ribelles, N; Rodríguez, CA; Ruiz, A; Salas, F; Soto, C	1
Cheng, B; Liu, K; Qiu, DB; Wang, GB	1
Depisch, D; Dworan, N; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Payrits, T; Scheithauer, W; Ulrich-Pur, H; Vormittag, L	1
Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC	1
Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A	1
Calvo, I; Carrasco, E; Casado, V; Casillas, M; Díaz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; San Antonio, B; Sánchez-Rovira, P	1
Dent, S; Messersmith, H; Trudeau, M	1
Branscheid, D; Droemann, D; Goldmann, T; Lang, DS; Martin, C; Ressmeyer, AR; Schultz, H; Vollmer, E; Zabel, P	1
Choi, YH; Chung, HC; Jeung, HC; Kim, BS; Rha, SY; Roh, JK; Yang, WI; Yoo, JH	1
Alés-Martínez, JE; Aramburo González, PM; Sánchez-Escribano Morcuende, R	1
Kibble, A	1
Chang, SY; Chang, WS; Kang, CY; Kim, YJ; Kim, YS; Ko, HJ; Ko, SY; Sakaguchi, S	1
El Khodary, AI; El Serafi, MM; El Zawahry, HR; Gaballa, HE; Mansour, OM	1
Iwata, H; Yamashita, T	1
Akasaka, H; Hara, Y; Hashimoto, H; Hayashi, K; Inokuchi, M; Kasahara, K; Miyamoto, K; Nakamura, M; Nishigami, J; Nishimura, G; Shimizu, M; Suga, Y; Yonejima, M	1
Xu, BH	1
Abbas, F; Gligorov, J; Khalil, A; Lotz, JP; Namer, M; Selle, F	1
Gluck, S; Lobo, C; Lopes, G; Silva, O	1
Bauer, RW; Eichler, K; Selby, JB; Vogl, TJ; Zangos, S	1
Cinieri, S; La Torre, I; Lorusso, V; Numico, G; Orlando, L; Pezzella, G; Silvestris, N	1
Jiang, WQ; Liu, DG; Teng, XY; Zhou, NN	1
Brunet, J; Colomer, R; De Llorens, R; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A	1
Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E	1
Alkis, N; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Er, O; Uner, A; Yamac, D; Yildiz, R	1
Altorjai, G; Bartsch, R; Dubsky, P; Gampenrieder, SP; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC	1
Awasthy, B; Chacko, RT; Dawar, R; Dhindsa, N; Hu, Z; Julka, PK; Koppiker, CB; Lin, B; Ma, D; Miller, ID; Nag, S; Nair, A; Nair, S; Oh, DS; Parshad, R; Perou, CM	1
Nagai, T; Ohgaki, K; Sugie, T	1
Dean-Colomb, W; Esteva, FJ	1
Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D	1
Adamo, B; Adamo, V; Condemi, G; Di Lullo, L; Ferrandina, G; Ferraro, G; Lorusso, D; Lorusso, V; Paglia, A; Pisconti, S; Priolo, D; Rossello, R; Scambia, G	1
Ang, PC; Chowbay, B; Khoo, KS; See, HT; Wong, NS; Wong, ZW	1
Csoka, K; Larsson, R; Liliemark, J; Nygren, P	1
Beykirch, M; Carmichael, J; Harris, AL; Kerr, H; Phillip, P; Possinger, K; Walling, J	1
Possinger, K	1
Carmichael, J; Walling, J	2
Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T	1
Boder, GB; Grindey, GB; Hertel, LW; Houghton, JA; Houghton, PJ; Merriman, RL; Rutherford, PG; Schultz, RM; Tanzer, LR	1
Von Hoff, DD	1
Kennedy, MJ	1
Awada, A; Klastersky, J	1
Malayeri, R; Wein, W; Zielinski, C	1
Budman, DR; Calabro, A; Kreis, W	1
Akrivakis, C; Flath, B; Grunewald, R; Lüftner, D; Mergenthaler, HG; Possinger, K	1
Akrivakis, C; Arning, M; Flath, B; Lüftner, D; Mergenthaler, HG; Ohnmacht, U; Possinger, K	1
Amadori, D; Barzanti, F; Casadei Giunchi, D; Dal Susino, M; Frassineti, GL; Milandri, C; Ricotti, L; Zoli, W	1
Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J	1
Arning, M; Coleman, R; Helsing, M; Kaufmann, M; Ohnmacht, U; Possinger, K; Stuart, NS	1
Akrivakis, K; Flath, B; Grosse, Y; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O	1
Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Püribauer, F; Scheithauer, W; Valencak, J; Weinländer, G	1
Adjei, AA; Erlichman, C	1
Burstein, HJ	1
Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C	1
Alonso, S; Barnadas, A; Carañana, V; Colomer, R; De Paz, L; Fernández, Y; Guillem, V; Llombart, A; Lluch, A; Ojeda, B	1
Abdel-Aziz, W; Hickey, RJ; Jiang, HY; Malkas, LH	1
Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P	1
Blitzer, JB; Evans, SS; Forsthoff, C; Link, JS; Nagourney, RA	1
Agostara, B; Gebbia, V; Leonardi, V; Valenza, R	1
Akrivakis, K; Flath, B; Mergenthaler, HG; Possinger, K; Schmid, P; Schweigert, M; Sezer, O	1
Alba, E; García-Conde, J; Khayat, D; Lluch, A; Moreno-Nogueira, JA; Palomero, M; Pérez-Manga, G; Rivelles, N	1
Aravantinos, G; Bafaloukos, D; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Nicolaides, C; Pavlidis, N; Samelis, G	1
Bafaloukos, D; Dimopoulos, MA; Fountzilas, G; Kalofonos, C; Kosmidis, P; Nicolaides, C; Pavlidis, N; Razi, E; Samantas, E	1
Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G	1
Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I	1
Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I	1
Bast, RC; Booser, D; Esteva, FJ; Esteva, FL; Hortobagyi, GN; Murray, JL; Rahman, Z; Rivera, E; Rosales, MM; Syrewicz, L; Theriault, RL; Valero, V	1
Hortobagyi, GN	2
Georgoulias, VA	1
Nagourney, RA	1
Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini'Neto, AO	1
Ansari, R; Gize, G; Miller, KD; Monaco, F; Nattam, S; Pennington, K; Sisk, J; Sledge, GW	1
Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B	1
Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P	1
Gnant, MF; Jakesz, R; Locker, GJ; Marosi, C; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC	1
Arends, J; Unger, C	1
Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E	1
Bontenbal, M; de Heus, G; de Wit, R; Seynaeve, C; Smorenburg, CH; van Zuylen, C; Verweij, J	1
Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B	1
Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini-Neto, AO	1
Cuvier, C; Diéras, V; Espié, M; Ferrero, JM; Fumoleau, P; Kalla, S; Kayitalire, L; Llombart-Cussac, A; Namer, M; Perrocheau, G; Ponzio, A; Pouillart, P; Spielmann, M	1
Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H	1
Robinson, BW; Shewach, DS	1
Bunnell, CA; Burstein, HJ; Winer, EP	1
Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ	1
de Mendoza, FH; Falcon, S; Gomez, H; Kahatt, C; Otero, J; Pen, DL; Santillana, S; Valdivia, S; Vallejos, C	1
Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R	1
Beryt, M; Felber, M; Hepp, H; Kahlert, S; Konecny, G; Langer, E; Lude, S; Pegram, M; Slamon, D; Untch, M	1
Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B	1
Burstein, HJ; Winer, EP	1
Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J	1
Athanasiadis, I; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdarides, D	1
Clarke, ML; Dumontet, C; Falette, N; Galmarini, CM; Mackey, JR; Puisieux, A	1
Bonadonna, G; Brambilla, C; Demicheli, R; Gianni, L; Marchianò, A; Mariani, G; Tagliabue, P; Valagussa, P; Villa, E; Zucchinelli, P	1
Ambinder, R; Blackstein, M; Cowan, J; Iglesias, J; Melemed, A; Vogel, CL	1
Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P	1
Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M	1
Salman, HS; Sparano, JA; Tanaka, K	1
Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P	1
Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O	1
Awada, A; Batter, V; Beex, L; Biganzoli, L; Cufer, T; Hamilton, A; Lohrisch, C; Nooij, M; Piccart, M	1
Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B	1
Algarra, I; Gaforio, JJ; Jaén, A; Lozano, A; Sánchez-Rovira, P; Serrano, MJ	1
Tripathy, D	2
Kimmel, G; Marsland, T; O'Shaughnessy, J; Pippen, J; Ratnam, S; Vukelja, SJ	1
Bunn, PA; Chan, DC; Franklin, WA; Helfrich, B; Hirsch, FR; Varella-Garcia, M	1
Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P	1

Reviews

93 review(s) available for gemcitabine and Breast Cancer

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Primary angiosarcoma of the breast: a case report and review of the literature. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2013, Volume: 96, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Developing Countries; Docetaxel; Female; Gemcitabine; Hemangiosarcoma; Humans; Lymph Node Excision; Magnetic Resonance Imaging; Mammaplasty; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Surgical Flaps; Taxoids; Thailand	2013
Unusual aggressive breast cancer: metastatic malignant phyllodes tumor. Journal of radiology case reports, 2013, Volume: 7, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Fibroadenoma; Gemcitabine; Humans; Ifosfamide; Muscle Neoplasms; Naphthacenes; Neoplasm Invasiveness; Palliative Care; Phyllodes Tumor; Prognosis	2013
Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials. Current medical research and opinion, 2013, Volume: 29, Issue:11 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Treatment Outcome	2013
[A case of gastric metastasis and carcinomatous peritonitis of breast cancer with improved QOL by stent implantation and gemcitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:8 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Peritonitis; Quality of Life; Stents; Stomach Neoplasms	2013
Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies. Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Asia, Western; Breast Neoplasms; China; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic	2014
Liposomal chemotherapeutics. Future oncology (London, England), 2013, Volume: 9, Issue:12 Topics: Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Multiple Myeloma; Paclitaxel; Pancreatic Neoplasms; Thyroid Neoplasms	2013
An update on PARP inhibitors--moving to the adjuvant setting. Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:1 Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Benzamides; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Gemcitabine; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors	2015
HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:15 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine	2008
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review. Health technology assessment (Winchester, England), 2008, Volume: 12, Issue:32 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab	2008
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. Journal of the National Cancer Institute, 2008, Dec-17, Volume: 100, Issue:24 Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome	2008
Gemcitabine for the treatment of metastatic breast cancer. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 2 Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Survival Analysis	2009
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? Journal of clinical apheresis, 2009, Volume: 24, Issue:5 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Plasma Exchange	2009
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes]. Magyar onkologia, 2010, Volume: 54, Issue:1 Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine	2010
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. Health technology assessment (Winchester, England), 2011, Volume: 15 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids	2011
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. The Lancet. Oncology, 2011, Volume: 12, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2011
[Role of gemcitabine in treatment of metastatic breast cancer]. Voprosy onkologii, 2011, Volume: 57, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Paclitaxel; Trastuzumab; Treatment Outcome	2011
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Paclitaxel; Taxoids	2012
Current approaches to the management of Her2-negative metastatic breast cancer. Breast cancer research : BCR, 2012, Apr-10, Volume: 14, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Deoxycytidine; Doxorubicin; Estradiol; Female; Fulvestrant; Gemcitabine; Humans; Megestrol; Ovary; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases	2012
Sorafenib in locally advanced or metastatic breast cancer. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles	2012
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials. Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult	2013
Gemcitabine and targeted therapy in metastatic breast cancer. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine	2002
[Gemcitabine and breast cancer]. Bulletin du cancer, 2002, Volume: 89 Spec No Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine	2002
Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 18 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Thymidylate Synthase	2002
Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology, 2003, Volume: 64, Issue:3 Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine	2003
Monotherapy options in the management of metastatic breast cancer. Seminars in oncology, 2003, Volume: 30, Issue:2 Suppl 3 Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine	2003
Gemcitabine and anthracyclines in breast cancer. Seminars in oncology, 2003, Volume: 30, Issue:2 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans	2003
Gemcitabine combined with docetaxel in metastatic breast cancer. Seminars in oncology, 2003, Volume: 30, Issue:2 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids	2003
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Seminars in oncology, 2003, Volume: 30, Issue:2 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Trastuzumab	2003
Rationale for the use of gemcitabine in breast cancer (Review). International journal of oncology, 2004, Volume: 24, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed; Taxoids; Trastuzumab; Vinblastine; Vinorelbine	2004
Single-agent gemcitabine in the treatment of advanced breast cancer. Clinical breast cancer, 2004, Volume: 4 Suppl 3 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Quality of Life; Treatment Outcome	2004
Gemcitabine and taxanes as a new standard of care in breast cancer. Clinical breast cancer, 2004, Volume: 4 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids	2004
Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clinical breast cancer, 2004, Volume: 4 Suppl 3 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids	2004
Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu. Clinical breast cancer, 2004, Volume: 4 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab	2004
Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer. Clinical breast cancer, 2004, Volume: 4 Suppl 3 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Research Design	2004
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine	2003
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12 Suppl 1 Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine	2003
Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12 Suppl 1 Topics: Adolescent; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Severity of Illness Index; Taxoids	2003
In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Taxoids	2004
Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Neoadjuvant Therapy; Taxoids	2004
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Neoplasms; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rats; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	2004
Gemcitabine and paclitaxel in metastatic breast cancer: a review. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome	2004
Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Taxoids; Time Factors; Treatment Outcome	2004
Gemcitabine and platinum-based chemotherapy in metastatic breast cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Treatment Outcome	2004
Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis	2004
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Antagonism; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Heart Failure; Humans; Platinum Compounds; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome	2004
Integrating gemcitabine into breast cancer therapy. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Treatment Outcome	2004
Gemcitabine in metastatic breast cancer. Expert review of anticancer therapy, 2005, Volume: 5, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Female; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome	2005
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology, 2005, Volume: 68, Issue:4-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome	2005
Gemcitabine plus paclitaxel in breast cancer. Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate	2005
Gemcitabine-taxane experience in the treatment of metastatic breast cancer. Cancer treatment reviews, 2005, Volume: 31 Suppl 4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Remission Induction; Taxoids; Treatment Outcome	2005
What is the best schedule for administration of gemcitabine-taxane? Cancer treatment reviews, 2005, Volume: 31 Suppl 4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Remission Induction; Taxoids; Trastuzumab	2005
Role of Gemcitabine in Breast Cancer Management: An Update. Seminars in oncology, 2006, Volume: 33, Issue:Suppl 2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2	2006
Optimizing adjuvant chemotherapy in early-stage breast cancer. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:14 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine	2005
Role of gemcitabine in cancer therapy. Future oncology (London, England), 2005, Volume: 1, Issue:1 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms	2005
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Lung Neoplasms; Lymphoma, Non-Hodgkin; Mucositis; Neoplasms; Prednisone; Radiotherapy; Severity of Illness Index; Stomatitis; Taxoids; Vinblastine; Vincristine; Vinorelbine	2006
[Chemotherapy for metastatic breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diphosphonates; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Meta-Analysis as Topic; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine	2006
Overview of gemcitabine activity in advanced breast cancer. Seminars in oncology, 2006, Volume: 33, Issue:3 Suppl 9 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids	2006
Gemcitabine: monochemotherapy of breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids	2006
Gemcitabine and taxanes in metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids	2006
Biological agents and gemcitabine in the treatment of breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Farnesyltranstransferase; Gemcitabine; Humans; Protein-Tyrosine Kinases; Ribonucleotide Reductases	2006
Clinical studies of pemetrexed and gemcitabine combinations. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Neoplasms; Pancreatic Neoplasms; Pemetrexed	2006
[Requirements for the development of molecularly defined targeted therapy in oncology]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Bevacizumab; Biomedical Research; Biotechnology; Breast Neoplasms; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computational Biology; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Industry; Female; Gemcitabine; Genome, Human; Humans; Imatinib Mesylate; Medical Oncology; Molecular Biology; Multicenter Studies as Topic; Neoplasms; Phenotype; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Trastuzumab; Treatment Outcome	2006
Usefulness of predictive tests for cancer treatment. Bulletin du cancer, 2006, Volume: 93, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Genes, ras; Humans; Lung Neoplasms; Membrane Glycoproteins; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Semaphorins; Taxoids; Ubiquitin-Protein Ligases	2006
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. The oncologist, 2006, Volume: 11 Suppl 1 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine	2006
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:19 Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors	2007
Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast cancer research and treatment, 2008, Volume: 108, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids	2008
[Current situation and features of chemotherapy for breast neoplasms]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Taxoids; Trastuzumab	2007
[Strategy in the treatment of anthracycline-resistant breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:4 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Taxoids; Vinblastine; Vinorelbine	2007
[Updates on gemcitabine on metastatic breast cancer]. Bulletin du cancer, 2007, Volume: 94 Spec No Actualites Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Trastuzumab; Vinblastine; Vinorelbine	2007
Role of gemcitabine in metastatic breast cancer patients: a short review. Breast (Edinburgh, Scotland), 2008, Volume: 17, Issue:3 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine	2008
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Seminars in oncology, 2008, Volume: 35, Issue:2 Suppl 2 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine	2008
Metastatic breast cancer. Current opinion in oncology, 1996, Volume: 8, Issue:6 Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome	1996
Advanced breast cancer: investigational role of gemcitabine. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans	1997
[Gemcitabine: a new chemotherapy agent for solid cancers]. Revue medicale de Bruxelles, 1997, Volume: 18, Issue:5 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents	1997
Gemcitabine for palliative treatment in metastatic breast cancer. Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:10 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Care	1998
Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Care	2001
Treatment of advanced breast cancer with gemcitabine and vinorelbine. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine	2001
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids	2001
Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Neoplasm Metastasis; Pemetrexed	2001
The evolving role of gemcitabine in the management of breast cancer. Oncology, 2001, Volume: 60, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans	2001
New combinations with epirubicin in advanced breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:5 Suppl 7 Topics: Adult; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Rate; Time Factors	2001
New cytotoxic agents and schedules for advanced breast cancer. Seminars in oncology, 2001, Volume: 28, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine	2001
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Seminars in oncology, 2001, Volume: 28, Issue:3 Suppl 10 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms	2001
New combinations with Herceptin in metastatic breast cancer. Oncology, 2001, Volume: 61 Suppl 2 Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine	2001
Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Ribonucleotide Reductases; Survival Analysis; Treatment Outcome	2002
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Drug Evaluation, Preclinical; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Ribonucleotide Reductases; Trastuzumab; Tumor Cells, Cultured	2002
Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed; Taxoids; Treatment Failure; Treatment Outcome	2002
Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome	2002
Gemcitabine/anthracycline combinations in metastatic breast cancer. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome	2002
Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Treatment Outcome; Vinblastine; Vinorelbine	2002
Gemcitabine in breast cancer: future directions. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Ribonucleotide Reductases	2002
Neoadjuvant gemcitabine therapy for breast cancer. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome	2002

Trials

235 trial(s) available for gemcitabine and Breast Cancer

Article	Year
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. JAMA network open, 2019, 11-01, Volume: 2, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2019
Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer. Medicine, 2019, Volume: 98, Issue:52 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclobutanes; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Pilot Projects; Survival Analysis	2019
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast cancer research : BCR, 2020, 10-23, Volume: 22, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Prognosis; Survival Rate; Treatment Outcome	2020
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial. BMC cancer, 2021, Jan-11, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Salvage Therapy; Young Adult	2021
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. Cancer research and treatment, 2021, Volume: 53, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asia; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Furans; Gemcitabine; Germ-Line Mutation; Humans; Ketones; Middle Aged; Phthalazines; Prognosis; Receptor, ErbB-2; Survival Rate; Vinorelbine	2021
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. Oncoimmunology, 2021, 05-11, Volume: 10, Issue:1 Topics: Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Prospective Studies; Retrospective Studies; Tumor Microenvironment	2021
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus ESMO open, 2021, Volume: 6, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Furans; Gemcitabine; Humans; Ketones; Nuclear Proteins; Paclitaxel; Pharmacogenomic Testing; Polymorphism, Genetic; Prospective Studies; Repressor Proteins	2021
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting	2017
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). British journal of cancer, 2017, Jun-27, Volume: 117, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting	2017
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015. Chemotherapy, 2017, Volume: 62, Issue:5 Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neutropenia; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2017
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. European journal of cancer (Oxford, England : 1990), 2017, Volume: 86 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Time Factors; Treatment Outcome; Young Adult	2017
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic oncology, 2018, Volume: 148, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome	2018
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Investigational new drugs, 2018, Volume: 36, Issue:2 Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quinolones; Treatment Outcome	2018
Pharmacometabonomics Analysis Reveals Serum Formate and Acetate Potentially Associated with Varying Response to Gemcitabine-Carboplatin Chemotherapy in Metastatic Breast Cancer Patients. Journal of proteome research, 2018, 03-02, Volume: 17, Issue:3 Topics: Acetates; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Formates; Gemcitabine; Humans; Lymphatic Metastasis; Magnetic Resonance Spectroscopy; Middle Aged; Prognosis; ROC Curve; Taxoids	2018
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides. British journal of clinical pharmacology, 2018, Volume: 84, Issue:6 Topics: Activation, Metabolic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cytidine Triphosphate; Deamination; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Leukocytes, Mononuclear; Phosphorylation; Uridine Triphosphate	2018
[A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Japanese Patients with Metastatic Breast Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Neoplasm Metastasis	2018
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. Breast cancer research and treatment, 2019, Volume: 175, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Patient Compliance; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Young Adult	2019
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can Cancer communications (London, England), 2019, 05-28, Volume: 39, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Receptor, ErbB-2; Republic of Korea; Surveys and Questionnaires	2019
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome	2013
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC cancer, 2013, Mar-28, Volume: 13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome	2013
A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. International journal of oncology, 2013, Volume: 42, Issue:5 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Staging; Pemetrexed; Taxoids; Vinblastine; Vinorelbine	2013
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Republic of Korea; Treatment Outcome; Watchful Waiting	2013
A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2013, Volume: 96 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy	2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids	2013
Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. European journal of radiology, 2013, Volume: 82, Issue:12 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemoembolization, Therapeutic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult	2013
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014, Volume: 16, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab	2014
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial The Lancet. Oncology, 2014, Volume: 15, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom	2014
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Membrane Transport Proteins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins	2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:2 Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Trastuzumab; Treatment Outcome	2014
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The oncologist, 2014, Volume: 19, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Prodrugs; Proportional Hazards Models; Taxoids; Treatment Outcome; Tubulin Modulators	2014
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. Future oncology (London, England), 2014, Volume: 10, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab	2014
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. Journal of the National Cancer Institute, 2014, May-15, Volume: 106, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids	2014
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. BMC cancer, 2014, May-22, Volume: 14 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome	2014
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome	2014
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Receptor, Angiotensin, Type 1; Receptor, ErbB-2; Survival Rate; Translational Research, Biomedical	2015
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Cohort Studies; Deoxycytidine; Docetaxel; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Salvage Therapy; Survival Analysis; Taxoids	2015
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, Apr-10, Volume: 6, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Genome-Wide Association Study; Humans; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Prognosis; Quantitative Trait Loci; Survival Analysis; Taxoids; Young Adult	2015
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast cancer research and treatment, 2015, Volume: 152, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome	2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:9 Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States	2015
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational new drugs, 2015, Volume: 33, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines	2015
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). Clinical breast cancer, 2016, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult	2016
Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes. Chemotherapy, 2016, Volume: 61, Issue:4 Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Remission Induction; Taxoids; Tomography, X-Ray Computed	2016
Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health and quality of life outcomes, 2016, Mar-25, Volume: 14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pain; Pain Measurement; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome	2016
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:2 Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel	2016
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial. Anticancer research, 2016, Volume: 36, Issue:9 Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids	2016
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. Clinical breast cancer, 2017, Volume: 17, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2017
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology, 2007, Volume: 73, Issue:5-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Thrombocytopenia	2007
Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clinical breast cancer, 2008, Volume: 8, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab	2008
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clinical breast cancer, 2008, Volume: 8, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance	2008
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate	2008
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-20, Volume: 26, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel	2008
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer, 2008, Nov-15, Volume: 113, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged	2008
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids	2009
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast cancer research and treatment, 2009, Volume: 116, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Middle Aged; Neoplasm Staging; Treatment Outcome	2009
Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer. Clinical breast cancer, 2008, Volume: 8, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local	2008
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clinical breast cancer, 2008, Volume: 8, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Receptor, ErbB-2; Trastuzumab	2008
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel	2009
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Taxoids	2009
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. Investigational new drugs, 2010, Volume: 28, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel	2010
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Survival Analysis; Taxoids	2009
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-01, Volume: 27, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic	2009
Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. Anticancer research, 2009, Volume: 29, Issue:5 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Taxoids	2009
Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule. Oncology, 2009, Volume: 77, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome	2009
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Investigational new drugs, 2010, Volume: 28, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Survival Analysis; Time Factors; Treatment Failure; Vinblastine; Vinorelbine	2010
A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3 Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Exanthema; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Pemetrexed; Pneumonia; Treatment Outcome	2010
Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. European radiology, 2010, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Liver Neoplasms; Middle Aged; Mitomycin; Prevalence; Survival Analysis; Survival Rate; Treatment Outcome	2010
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clinical breast cancer, 2009, Volume: 9, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2009
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Investigational new drugs, 2010, Volume: 28, Issue:6 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome	2010
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. Oncology, 2009, Volume: 77, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids	2009
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati Breast cancer research and treatment, 2010, Volume: 119, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors	2010
Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment. Japanese journal of clinical oncology, 2009, Volume: 39, Issue:11 Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Taxoids; Treatment Outcome	2009
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome	2010
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Salvage Therapy; Taxoids	2010
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:7 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome	2010
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast American journal of clinical oncology, 2010, Volume: 33, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab	2010
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer research, 2010, Volume: 30, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines	2010
A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer. Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:1 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine	2010
A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy. Clinical breast cancer, 2010, Volume: 10, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Salvage Therapy; Taxoids; Treatment Outcome	2010
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer. Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoadjuvant Therapy; Patient Selection; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2011
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer. Clinical breast cancer, 2010, Volume: 10, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome	2010
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ribonucleoside Diphosphate Reductase; Survival; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult	2011
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast cancer research and treatment, 2010, Volume: 123, Issue:2 Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Florida; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2010
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Phenotype; Receptor, ErbB-2	2011
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clinical breast cancer, 2010, Oct-01, Volume: 10, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Recombinant Proteins	2010
Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer research, 2010, Volume: 30, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Taxoids	2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids	2011
A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment. Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:4 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome	2010
Iniparib plus chemotherapy in metastatic triple-negative breast cancer. The New England journal of medicine, 2011, Jan-20, Volume: 364, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Carboplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis	2011
Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome	2012
Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients. American journal of clinical oncology, 2012, Volume: 35, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Injections, Intravenous; Middle Aged; Neutropenia; Polyethylene Glycols; Stomatitis; Thrombocytopenia; Treatment Outcome	2012
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome	2011
Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine	2012
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British journal of cancer, 2011, Mar-29, Volume: 104, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine	2011
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast cancer (Tokyo, Japan), 2011, Volume: 18, Issue:3 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome	2011
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Watchful Waiting	2011
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC cancer, 2011, Apr-12, Volume: 11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult	2011
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Drugs in R&D, 2011, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult	2011
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clinical breast cancer, 2011, Volume: 11, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome	2011
Long-term gemcitabine administration in heavily pretreated Japanese patients with metastatic breast cancer: additional safety analysis of a phase II study. Breast cancer (Tokyo, Japan), 2012, Volume: 19, Issue:4 Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heart Failure; Humans; Middle Aged; Taxoids; Unconsciousness	2012
Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2012, Volume: 21, Issue:5 Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Data Collection; Deoxycytidine; Female; Gemcitabine; Health Status Indicators; Humans; Internationality; Middle Aged; Paclitaxel; Pain Measurement; Psychometrics; Quality of Life; Stress, Psychological; Treatment Outcome	2012
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine	2012
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer. Investigational new drugs, 2012, Volume: 30, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2	2012
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Dec-20, Volume: 29, Issue:36 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids	2011
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study. Oncology, 2011, Volume: 81, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Middle Aged	2011
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. Breast cancer research and treatment, 2012, Volume: 132, Issue:2 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome	2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England journal of medicine, 2012, Jan-26, Volume: 366, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome	2012
Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5 Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Prognosis; Prospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine	2012
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome	2012
A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up. Breast cancer (Tokyo, Japan), 2013, Volume: 20, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Survival Rate	2013
A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes. Hematology/oncology and stem cell therapy, 2012, Volume: 5, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy	2012
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2012, Volume: 14, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide; Receptors, Estrogen; Survivin	2012
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer. Clinical breast cancer, 2012, Volume: 12, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids	2012
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. Clinical breast cancer, 2013, Volume: 13, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult	2013
New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers. American journal of clinical oncology, 2014, Volume: 37, Issue:4 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms	2014
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials. International journal of cancer, 2013, Aug-15, Volume: 133, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Prognosis; Survival Analysis; Taxoids	2013
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:6 Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Treatment Outcome	2002
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2). American journal of clinical oncology, 2002, Volume: 25, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms	2002
Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer. Cancer investigation, 2002, Volume: 20, Issue:7-8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome	2002
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. British journal of cancer, 2003, Feb-24, Volume: 88, Issue:4 Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Heart Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Salvage Therapy; Soft Tissue Neoplasms	2003
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast cancer research and treatment, 2003, Volume: 78, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine	2003
Gemcitabine and trastuzumab in metastatic breast cancer. Seminars in oncology, 2003, Volume: 30, Issue:2 Suppl 3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab	2003
Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial. Clinical breast cancer, 2003, Volume: 4, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Prognosis; Vinblastine; Vinorelbine	2003
Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. Oncology, 2003, Volume: 64, Issue:4 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Middle Aged; Treatment Outcome	2003
Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study. Oncology, 2003, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine	2003
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine	2003
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. Journal of clinical laboratory analysis, 2003, Volume: 17, Issue:5 Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast; Breast Neoplasms; Cisplatin; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; DNA, Complementary; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Sensitivity and Specificity; Sequence Analysis, DNA; Tumor Suppressor Proteins	2003
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Survival Analysis; Treatment Outcome	2003
Doxorubicin, paclitaxel and gemcitabine: a Phase I study of a new sequential treatment in stage III B - IV breast cancer. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Paclitaxel	2003
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids	2004
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome	2004
Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12 Suppl 1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Selection; Survival Rate; Treatment Outcome; World Health Organization	2003
Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12 Suppl 1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection; Salvage Therapy; Survival Analysis; Trastuzumab; Treatment Outcome; World Health Organization	2003
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12 Suppl 1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab; Treatment Outcome	2003
Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology, 2004, Volume: 66, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome	2004
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 5 Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Survival Analysis; Taxoids	2004
Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Taxoids	2004
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Taxoids	2004
Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clinical breast cancer, 2004, Volume: 5, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Risk Assessment; Survival Analysis; Treatment Outcome	2004
Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clinical breast cancer, 2004, Volume: 5, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Risk Factors; Survival Analysis; Trastuzumab; Treatment Outcome	2004
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study. American journal of clinical oncology, 2004, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis	2004
Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences. Pharmacy world & science : PWS, 2004, Volume: 26, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Forecasting; Gemcitabine; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Italy; Kinetics; Lymphoma, Non-Hodgkin; Vinblastine; Vinorelbine	2004
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome	2004
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology, 2004, Volume: 67, Issue:3-4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome	2004
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer investigation, 2004, Volume: 22, Issue:5 Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neutropenia; Paclitaxel; Trastuzumab; Treatment Outcome	2004
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial. Anti-cancer drugs, 2005, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome	2005
Neoadjuvant therapy with gemcitabine in breast cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome	2004
Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. American journal of clinical oncology, 2005, Volume: 28, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis	2005
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:6 Topics: Aged; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause	2005
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast cancer research and treatment, 2005, Volume: 90, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Analysis; Treatment Outcome	2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical breast cancer, 2005, Volume: 6, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Salvage Therapy; Skin Neoplasms; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Vomiting	2005
Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer. Onkologie, 2005, Volume: 28, Issue:6-7 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Metabolic Clearance Rate; Middle Aged; Severity of Illness Index; Tissue Distribution; Trastuzumab	2005
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clinical breast cancer, 2005, Volume: 6, Issue:2 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome	2005
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study. Investigational new drugs, 2005, Volume: 23, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neutropenia	2005
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology, 2005, Volume: 68, Issue:4-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome	2005
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Liposomes; Mastectomy, Segmental; Middle Aged; Taxoids; Treatment Outcome	2005
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:9 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2005
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. Anti-cancer drugs, 2005, Volume: 16, Issue:9 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome	2005
High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Salvage Therapy; Taxoids; Time Factors	2006
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Polyethylene Glycols; Quality of Life; Survival Rate; Treatment Outcome	2006
Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure. Cancer investigation, 2005, Volume: 23, Issue:5 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome	2005
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Pemetrexed; Survival Analysis	2006
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study. BMC cancer, 2005, Nov-29, Volume: 5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome	2005
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients? Cancer treatment reviews, 2005, Volume: 31 Suppl 4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids	2005
High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:8 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab	2005
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial. Clinical breast cancer, 2005, Volume: 6, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids	2005
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. BMC cancer, 2006, Feb-24, Volume: 6 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors	2006
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC cancer, 2006, Mar-21, Volume: 6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome	2006
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer. Clinical breast cancer, 2006, Volume: 6, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome	2006
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anti-cancer drugs, 2006, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis	2006
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. BMC cancer, 2006, May-24, Volume: 6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome	2006
Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate	2006
Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2 Topics: Adult; Aged; Alopecia; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Recurrence; Severity of Illness Index; Stomatitis; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome	2007
Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncology reports, 2006, Volume: 16, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Vinblastine; Vinorelbine	2006
Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. American journal of clinical oncology, 2006, Volume: 29, Issue:5 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Taxoids	2006
Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70 years) women with metastatic breast cancer? Early interruption of a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Quality of Life; Survival Rate; Vinblastine; Vinorelbine	2007
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study. Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Metastasis; Treatment Outcome	2006
Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. Oncology, 2006, Volume: 70, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis; Treatment Outcome	2006
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Vinblastine; Vinorelbine	2006
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. The Lancet. Oncology, 2007, Volume: 8, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vinblastine; Vinorelbine	2007
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction	2007
Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer. Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Polyethylene Glycols; Survival; Treatment Outcome	2007
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors. Oncology research, 2006, Volume: 16, Issue:6 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome	2006
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids	2007
Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:7 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Secondary Prevention; Survival Analysis; Taxoids	2007
Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study. Journal of the Egyptian National Cancer Institute, 2006, Volume: 18, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Treatment Outcome	2006
[Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting	2007
Study supports activity of gemcitabine in treatment of early-stage breast cancer. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging	2007
Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Investigational new drugs, 2008, Volume: 26, Issue:4 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome	2008
A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. British journal of cancer, 2008, Apr-22, Volume: 98, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Prognosis	2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast cancer research and treatment, 2009, Volume: 115, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab	2009
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. British journal of cancer, 2008, Jun-17, Volume: 98, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Recurrence; Treatment Outcome	2008
Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer. Breast (Edinburgh, Scotland), 2008, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Treatment Outcome	2008
Advanced breast cancer: a phase II trial with gemcitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:11 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Remission Induction; Vomiting	1995
Phase II activity of gemcitabine in advanced breast cancer. Seminars in oncology, 1996, Volume: 23, Issue:5 Suppl 10 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged	1996
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms	1996
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Investigational new drugs, 1998, Volume: 16, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging	1998
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:2 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids	1999
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-cancer drugs, 1999, Volume: 10, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Quality of Life; Treatment Outcome	1999
Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-cancer drugs, 1999, Volume: 10, Issue:7 Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis	1999
Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast cancer research and treatment, 1999, Volume: 55, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine	1999
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer. Seminars in oncology, 1999, Volume: 26, Issue:2 Suppl 6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pemetrexed	1999
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed	2000
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction	2000
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine	2000
Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Treatment Outcome; Vinblastine; Vinorelbine	2000
Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anti-cancer drugs, 1999, Volume: 10, Issue:6 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphangioma; Middle Aged	1999
Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:13 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Survival Rate	2000
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer investigation, 2000, Volume: 18, Issue:6 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids	2000
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine	2000
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 2000, Volume: 12, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia	2000
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome	2001
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Gemcitabine; Humans; Liposomes; Middle Aged; Neutropenia	2001
Gemcitabine plus cisplatin in breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis	2001
Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome	2001
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab	2001
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel	2001
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:2 Suppl 3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia	2001
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast cancer research and treatment, 2001, Volume: 66, Issue:1 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Palliative Care; Taxoids; Treatment Failure	2001
Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. American journal of clinical oncology, 2001, Volume: 24, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy	2001
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology, 2001, Volume: 60, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Remission Induction; Safety; Vomiting	2001
A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report. Seminars in oncology, 2001, Volume: 28, Issue:3 Suppl 10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy	2001
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study. Seminars in oncology, 2001, Volume: 28, Issue:3 Suppl 10 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel	2001
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast cancer research and treatment, 2001, Volume: 68, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome	2001
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome	2001
Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-01, Volume: 20, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Vinblastine; Vinorelbine	2002
Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer. Breast cancer research and treatment, 2001, Volume: 70, Issue:3 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Menopause; Middle Aged; Vinblastine; Vinorelbine	2001
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology, 2002, Volume: 62, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pain Measurement; Receptors, Estrogen; Survival Analysis; Time Factors; Treatment Outcome	2002
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. Oncology, 2002, Volume: 62, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids	2002
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Oncology, 2002, Volume: 62, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization	2002
Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes. Clinical breast cancer, 2002, Volume: 2, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bilirubin; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome	2002
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer. Clinical breast cancer, 2000, Volume: 1, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome	2000
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:6 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids	2002
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome	2002
Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clinical breast cancer, 2002, Volume: 3 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis; Trastuzumab; Treatment Failure; Treatment Outcome	2002

Other Studies

239 other study(ies) available for gemcitabine and Breast Cancer

Article	Year
Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors. Journal of medicinal chemistry, 2007, Nov-01, Volume: 50, Issue:22 Topics: Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Indazoles; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Structure-Activity Relationship	2007
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved? European journal of medicinal chemistry, 2021, Jan-15, Volume: 210 Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2	2021
Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network. Dermatology (Basel, Switzerland), 2022, Volume: 238, Issue:3 Topics: Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2022
Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors. ACS applied materials & interfaces, 2021, Oct-06, Volume: 13, Issue:39 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chondroitin Sulfates; Delayed-Action Preparations; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Hydrogels; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, Inbred BALB C; Micelles; Neoplasm Metastasis; Poloxamer; Tryptophan; Tumor Microenvironment	2021
MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH. Cell death & disease, 2021, 09-22, Volume: 12, Issue:10 Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; HEK293 Cells; Humans; Male; Membrane Proteins; Mice, Inbred BALB C; MicroRNAs; Neoplasm Invasiveness; Neoplasm Proteins; Prognosis; RNA-Binding Proteins	2021
ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression. Cancer research, 2021, 12-01, Volume: 81, Issue:23 Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Movement; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immune Tolerance; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid-Derived Suppressor Cells; Neoplasm Invasiveness; Neoplastic Stem Cells; Prognosis; Recombinant Proteins; Retinal Dehydrogenase; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2021
Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer. Biomaterials, 2022, Volume: 280 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Imiquimod; Mice; Nanoparticles	2022
Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicology and applied pharmacology, 2022, 02-15, Volume: 437 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Kaempferols; Nanog Homeobox Protein; Neoplastic Stem Cells; Verapamil	2022
Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines. PloS one, 2022, Volume: 17, Issue:5 Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Progesterone; Receptors, Progesterone	2022
Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy. Molecular pharmaceutics, 2022, 07-04, Volume: 19, Issue:7 Topics: Animals; Annexin A5; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Fluorescein-5-isothiocyanate; Gemcitabine; Humans; Mice; Mucin-1; Nanoparticles; Polyesters; Polyethylene Glycols	2022
Ameliorating the antitumor activity of gemcitabine against breast tumor using α Drug development and industrial pharmacy, 2022, Volume: 48, Issue:8 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Gemcitabine; Humans; Integrin alphaV; Integrin beta3; Ligands; Mice; Mice, Inbred BALB C; Nanoparticles	2022
Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer. BMJ case reports, 2022, Nov-01, Volume: 15, Issue:11 Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Gemcitabine; Humans; Ischemia; Middle Aged	2022
Comment on: "Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy". Molecular pharmaceutics, 2023, 02-06, Volume: 20, Issue:2 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Gemcitabine; Humans; Mucin-1; Nanoparticles; Polyesters; Polyethylene Glycols	2023
Engineered Cancer-Derived Small Extracellular Vesicle-Liposome Hybrid Delivery System for Targeted Treatment of Breast Cancer. ACS applied materials & interfaces, 2023, Apr-05, Volume: 15, Issue:13 Topics: Breast Neoplasms; Drug Delivery Systems; Extracellular Vesicles; Female; Gemcitabine; Humans; Liposomes	2023
Avelumab in metastatic collecting duct carcinoma of the kidney: a case report. Journal of medical case reports, 2023, Jun-13, Volume: 17, Issue:1 Topics: Aged; Breast Neoplasms; Carcinoma, Renal Cell; Cisplatin; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Male; Neoplasms, Second Primary; Quality of Life	2023
Gemcitabine-associated digital necrosis in metastatic breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:7 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Necrosis; Thrombosis	2023
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). Breast cancer research and treatment, 2019, Volume: 178, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Multicenter Studies as Topic; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Risk Factors; Treatment Outcome; Young Adult	2019
Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells. Journal of microbiology and biotechnology, 2019, Nov-28, Volume: 29, Issue:11 Topics: Antineoplastic Agents; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Gemcitabine; Humans; MCF-7 Cells; Nucleolin; Phosphoproteins; RNA-Binding Proteins	2019
MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. Neoplasma, 2020, Volume: 67, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MicroRNAs; Neoplasm Proteins	2020
Drug-loaded implantable surgical cavity-adaptive hydrogels for prevention of local tumor recurrence. International journal of pharmaceutics, 2020, Mar-15, Volume: 577 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Drug Implants; Drug Synergism; Female; Gemcitabine; Hyaluronic Acid; Hydrogels; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Xenograft Model Antitumor Assays	2020
Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity. Pharmaceutical development and technology, 2020, Volume: 25, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Stability; Emulsions; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Nanoparticles; Oligopeptides; Particle Size; Rats; Rats, Sprague-Dawley; Surface Properties; Xenograft Model Antitumor Assays	2020
Complete Response of a Pleural, Hepatic, and Splenic Metastatic Primary Breast Angiosarcoma Using Gemcitabine Monotherapy. JCO oncology practice, 2020, Volume: 16, Issue:4 Topics: Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Hemangiosarcoma; Humans; Splenic Neoplasms	2020
Gemcitabine Co-Encapsulated with Curcumin in Folate Decorated PLGA Nanoparticles; a Novel Approach to Treat Breast Adenocarcinoma. Pharmaceutical research, 2020, Feb-18, Volume: 37, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Gemcitabine; Humans; Mice, Nude; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer	2020
A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships. The AAPS journal, 2020, 03-02, Volume: 22, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Lab-On-A-Chip Devices; MCF-7 Cells; Microfluidic Analytical Techniques; Models, Biological; Perfusion; Proof of Concept Study; Tissue Culture Techniques	2020
Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. PloS one, 2020, Volume: 15, Issue:3 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Deoxycytidine; Dose-Response Relationship, Drug; Drug Compounding; Drug Synergism; Female; Gemcitabine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Treatment Outcome	2020
Cardiac Masses in a Patient With Pancreatic Adenocarcinoma and a History of Breast Carcinoma. JAMA oncology, 2020, 06-01, Volume: 6, Issue:6 Topics: Adenocarcinoma; Albumins; Anticoagulants; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombosis; Warfarin	2020
Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Molecular cancer therapeutics, 2020, Volume: 19, Issue:8 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2020
Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal. Oncogene, 2020, Volume: 39, Issue:31 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Self Renewal; Deoxycytidine; Doxorubicin; Female; Gemcitabine; HEK293 Cells; Heterografts; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Methyltransferases; Proto-Oncogene Proteins p21(ras); Trans-Activators; Transcriptional Coactivator with PDZ-Binding Motif Proteins	2020
Co-delivery of gemcitabine prodrug along with anti NF-κB siRNA by tri-layer micelles can increase cytotoxicity, uptake and accumulation of the system in the cancers. Materials science & engineering. C, Materials for biological applications, 2020, Volume: 116 Topics: Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Liver Neoplasms; Micelles; NF-kappa B; Polyethylene Glycols; Prodrugs; RNA, Small Interfering	2020
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast cancer research and treatment, 2020, Volume: 184, Issue:2 Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Liver; Lung Neoplasms; Retrospective Studies; Survival Analysis	2020
Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules. Pharmaceutical research, 2020, Sep-23, Volume: 37, Issue:10 Topics: Animals; Breast Neoplasms; Deoxycytidine; Drug Combinations; Drug Delivery Systems; Female; Gemcitabine; Kidney; Liver; Lung; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Spleen; Tissue Distribution	2020
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. International journal of molecular sciences, 2020, Nov-27, Volume: 21, Issue:23 Topics: Apoptosis; Breast Neoplasms; Carboplatin; Caspases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Platinum	2020
[A Case of Ipsilateral Breast Tumor Recurrence(IBTR)after Breast-Conserving Surgery Which Successfully Resected after Chemotherapy Using Carboplatin plus Gemcitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13 Topics: Adult; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Mastectomy, Segmental; Neoplasm Recurrence, Local	2020
First-line Gemcitabine Anticancer research, 2021, Volume: 41, Issue:3 Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Physicians; Prospective Studies; Quality of Life; Treatment Failure	2021
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells, 2021, 04-06, Volume: 10, Issue:4 Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay	2021
Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2021, Oct-01, Volume: 165 Topics: Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chitosan; Deoxycytidine; Female; Folic Acid; Gemcitabine; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Nanoparticles; Particle Size; Rats; Silver	2021
Biotinylated Mn International journal of pharmaceutics, 2021, Sep-05, Volume: 606 Topics: Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Nanoparticles; Polyethylene Glycols	2021
Gemcitabine Integrated Nano-Prodrug Carrier System. Bioconjugate chemistry, 2017, 05-17, Volume: 28, Issue:5 Topics: Amyloid; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Nanofibers; Nanostructures; Prodrugs; Tumor Cells, Cultured	2017
Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells. Molecular therapy : the journal of the American Society of Gene Therapy, 2017, 07-05, Volume: 25, Issue:7 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipoproteins, LDL; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Nanoparticles; Receptors, LDL; Squalene; Tumor Burden; Xenograft Model Antitumor Assays	2017
Positively charged cyclodextrins as effective molecular transporters of active phosphorylated forms of gemcitabine into cancer cells. Scientific reports, 2017, 08-21, Volume: 7, Issue:1 Topics: Antimetabolites, Antineoplastic; Biological Transport; Breast Neoplasms; Cyclodextrins; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Models, Theoretical; Phosphorylation; Tumor Cells, Cultured	2017
Gemcitabine-Induced Retinopathy. Retina (Philadelphia, Pa.), 2017, Volume: 37, Issue:11 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorescein Angiography; Gemcitabine; Humans; Intravitreal Injections; Middle Aged; Neoplasm Staging; Retinal Diseases; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Vision Disorders	2017
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer. Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Receptor, ErbB-2; Receptors, Estrogen; Retreatment; Trastuzumab; Treatment Outcome	2018
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer. Cancer discovery, 2018, Volume: 8, Issue:2 Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms	2018
MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC cancer, 2018, 01-12, Volume: 18, Issue:1 Topics: Breast Neoplasms; Carrier Proteins; Cell Cycle Proteins; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MCF-7 Cells; MicroRNAs; Nuclear Proteins; Prognosis; Transcription Factors	2018
Effective light-triggered contents release from helper lipid-incorporated liposomes co-encapsulating gemcitabine and a water-soluble photosensitizer. International journal of pharmaceutics, 2018, Apr-05, Volume: 540, Issue:1-2 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Drug Compounding; Drug Liberation; Female; Gemcitabine; Infrared Rays; Kinetics; Lipids; Liposomes; Mice; Photosensitizing Agents; Porphyrins; Solubility; Technology, Pharmaceutical; Water	2018
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. Journal of the National Cancer Institute, 2018, 08-01, Volume: 110, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germ-Line Mutation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Maintenance Chemotherapy; Resorcinols; Treatment Outcome	2018
N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. Journal of controlled release : official journal of the Controlled Release Society, 2018, 05-10, Volume: 277 Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Breast Neoplasms; Caco-2 Cells; Cell Survival; Chitosan; Deoxycytidine; Female; Gemcitabine; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Peptide Fragments; Rats; Rats, Sprague-Dawley; Swine; Treatment Outcome	2018
Zein Microneedles for Localized Delivery of Chemotherapeutic Agents to Treat Breast Cancer: Drug Loading, Release Behavior, and Skin Permeation Studies. AAPS PharmSciTech, 2018, Volume: 19, Issue:4 Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Excipients; Female; Gemcitabine; Humans; Microinjections; Needles; Organ Culture Techniques; Skin; Skin Absorption; Solubility; Swine; Tamoxifen; Zein	2018
Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management. Acta biomaterialia, 2018, Volume: 73 Topics: Albumins; Anacardic Acids; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Clathrin; Deoxycytidine; Docetaxel; Drug Carriers; Female; Gemcitabine; Hemolysis; Humans; Macromolecular Substances; MCF-7 Cells; Nanoparticles; Neoplasm Transplantation; Particle Size; Polymers; Protein Conformation; Rats; Rats, Sprague-Dawley	2018
Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy. Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Micelles; Nanoparticles; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. Blood advances, 2018, 08-14, Volume: 2, Issue:15 Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasms, Second Primary; Nivolumab; Rituximab; Syndrome	2018
A facile route to heterotelechelic polymer prodrug nanoparticles for imaging, drug delivery and combination therapy. Journal of controlled release : official journal of the Controlled Release Society, 2018, 09-28, Volume: 286 Topics: Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Female; Fluorescent Dyes; Gemcitabine; Humans; MCF-7 Cells; Nanoparticles; Optical Imaging; Polymers; Prodrugs; Rhodamines	2018
Gemcitabine delivered by fucoidan/chitosan nanoparticles presents increased toxicity over human breast cancer cells. Nanomedicine (London, England), 2018, Volume: 13, Issue:16 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Drug Delivery Systems; Endothelial Cells; Gemcitabine; Humans; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Polymers; Polysaccharides	2018
Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. Cancer, 2018, 12-15, Volume: 124, Issue:24 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Linear Models; Neoplasm Staging; Retrospective Studies; SEER Program; Survival Analysis	2018
Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment. Molecules (Basel, Switzerland), 2018, Nov-07, Volume: 23, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Gemcitabine; Lipids; Mice; Nanoparticles; Oligopeptides; Paclitaxel; Tissue Distribution	2018
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. International journal of cancer, 2019, 05-15, Volume: 144, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Nestin; Phosphoric Monoester Hydrolases; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies	2019
Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity. Journal of controlled release : official journal of the Controlled Release Society, 2019, 02-10, Volume: 295 Topics: Breast Neoplasms; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Combinations; Drug Synergism; Female; Gemcitabine; Humans; Lapatinib; MCF-7 Cells; Nanoparticles; Polymerization; Prodrugs	2019
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow? Chinese clinical oncology, 2019, Volume: 8, Issue:S1 Topics: Albumins; Biomarkers; Breast Neoplasms; Caveolin 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel	2019
Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells. Bosnian journal of basic medical sciences, 2019, Nov-08, Volume: 19, Issue:4 Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drosophila melanogaster; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; HCT116 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; MCF-7 Cells; Phosphotransferases (Alcohol Group Acceptor); Recombinant Proteins; Substrate Specificity; Transfection	2019
Tumor-specific delivery of gemcitabine with activatable liposomes. Journal of controlled release : official journal of the Controlled Release Society, 2019, 09-10, Volume: 309 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Hyperthermia, Induced; Liposomes; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Temperature	2019
Tailoring the Chemical Modification of Chitosan Hydrogels to Fine-Tune the Release of a Synergistic Combination of Chemotherapeutics. Biomacromolecules, 2019, 08-12, Volume: 20, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chitosan; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Female; Gemcitabine; Humans; Hydrogels; Polymers	2019
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anti-cancer drugs, 2012, Volume: 23, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Mitochondria; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor	2012
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system. Anti-cancer drugs, 2012, Volume: 23, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids	2012
[A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Remission Induction	2013
Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate	2013
SL-01, an oral derivative of gemcitabine, inhibited human breast cancer growth through induction of apoptosis. Biochemical and biophysical research communications, 2013, Aug-23, Volume: 438, Issue:2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Design; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Xenograft Model Antitumor Assays	2013
Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology, 2013, Volume: 85, Issue:4 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking	2013
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. Cellular oncology (Dordrecht), 2013, Volume: 36, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paclitaxel; Polyethylene Glycols; Time Factors; Treatment Outcome; Tumor Burden	2013
[Clinical experience with gemcitabine treatment for metastatic breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quality of Life; Recurrence	2013
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. BMC cancer, 2013, Nov-12, Volume: 13 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Deoxycytidine; Disease Progression; DNA Copy Number Variations; Docetaxel; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Taxoids; Treatment Outcome; Tumor Suppressor Proteins	2013
[Gemcitabine-induced tumor lysis syndrome caused by recurrent breast cancer in a patient without hemodialysis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:11 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Recurrence; Tumor Lysis Syndrome	2013
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2015, Volume: 24, Issue:1 Topics: Adult; Aged; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Health Services Needs and Demand; Health Status; Humans; Longitudinal Studies; Middle Aged; Pancreatic Neoplasms; Quality of Life; Response Evaluation Criteria in Solid Tumors	2015
Sulforaphane inhibits growth of human breast cancer cells and augments the therapeutic index of the chemotherapeutic drug, gemcitabine. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:10 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Synergism; Female; Gemcitabine; Humans; Isothiocyanates; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2; Sulfoxides	2013
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Messenger; Taxoids	2014
[A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Receptor, ErbB-2; Trastuzumab	2013
Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. Journal of the American Chemical Society, 2014, Feb-26, Volume: 136, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Dendrimers; Deoxycytidine; Drug Carriers; Female; Flow Cytometry; Gemcitabine; Mice; Microscopy, Electron, Transmission; Polyethylene Glycols; Positron-Emission Tomography	2014
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Community Mental Health Centers; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Medical Oncology; Middle Aged; Retrospective Studies; Vinblastine; Vinorelbine	2015
Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. The Journal of biological chemistry, 2014, May-09, Volume: 289, Issue:19 Topics: Animals; Antimetabolites, Antineoplastic; Bacterial Proteins; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Mice; Mycoplasma hyorhinis; Mycoplasma Infections; Pyrimidine Phosphorylases; Tetrahydrouridine; Thymidine; Tumor Microenvironment	2014
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:7 Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine	2014
The targeting mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced tumor therapy. Oncotarget, 2014, Jun-15, Volume: 5, Issue:11 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Docosahexaenoic Acids; Female; Gemcitabine; Hep G2 Cells; Humans; Ligands; Liver Neoplasms; MCF-7 Cells; Mice; Mice, Nude; Molecular Targeted Therapy; Phosphatidylethanolamines; Random Allocation; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2014
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein. BMC cancer, 2014, Aug-16, Volume: 14 Topics: Breast Neoplasms; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Deoxyuridine; Female; Gemcitabine; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Radiation-Sensitizing Agents	2014
Anticancer effects of brucine and gemcitabine combination in MCF-7 human breast cancer cells. Natural product research, 2015, Volume: 29, Issue:5 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Cycle; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; MCF-7 Cells; Strychnine	2015
Effects of doxorubicin and gemcitabine on the induction of apoptosis in breast cancer cells. Oncology reports, 2014, Volume: 32, Issue:6 Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; MCF-7 Cells; Mice; Neoplastic Stem Cells	2014
Gemcitabine interacts with carbonate apatite with concomitant reduction in particle diameter and enhancement of cytotoxicity in breast cancer cells. Current drug delivery, 2015, Volume: 12, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Apatites; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Resistance, Neoplasm; Endocytosis; Female; Gemcitabine; Humans; MCF-7 Cells; Nanoparticles; Particle Size	2015
Irinotecan as a palliative therapy for metastatic breast cancer patients after previous chemotherapy. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:24 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate	2014
Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. Cancer research, 2015, Apr-01, Volume: 75, Issue:7 Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Cell Cycle; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Cytidine Deaminase; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; MCF-7 Cells; MicroRNAs; Proportional Hazards Models; RNA Interference	2015
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer. Journal of the Egyptian National Cancer Institute, 2015, Volume: 27, Issue:3 Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography	2015
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. Oncology reports, 2015, Volume: 34, Issue:1 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Maytansine; MCF-7 Cells; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Up-Regulation	2015
Expression of XB130 in human ductal breast cancer. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mastectomy; MCF-7 Cells; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Risk Factors; RNA Interference; Signal Transduction; Time Factors; Transfection; Treatment Outcome; Up-Regulation	2015
Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo. Drug design, development and therapy, 2015, Volume: 9 Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Deoxycytidine; Drosophila Proteins; Female; Gemcitabine; Genes, Transgenic, Suicide; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Phosphotransferases (Alcohol Group Acceptor); Time Factors; Transduction, Genetic; Virus Replication; Xenograft Model Antitumor Assays	2015
[A Case of Gastrointestinal Metastases of Breast Cancer Effectively Treated with Gemcitabine and Paclitaxel Combination Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Intestinal Obstruction; Middle Aged; Paclitaxel; Stomach Neoplasms	2015
Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer. Journal of pharmaceutical sciences, 2015, Volume: 104, Issue:12 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays	2015
Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning. Molecular oncology, 2016, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Machine Learning; Paclitaxel; Support Vector Machine	2016
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nature communications, 2015, Nov-04, Volume: 6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab	2015
MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays	2016
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:18 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Sectional Studies; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Iran; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life	2015
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Molecular oncology, 2016, Volume: 10, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Benzimidazoles; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Female; Fluorine Radioisotopes; Gemcitabine; Humans; Mice; Mice, Nude; Misonidazole; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Quinolones	2016
Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer. Archives of pharmacal research, 2016, Volume: 39, Issue:3 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Liposomes; Particle Size; Polyethylene Glycols; Surface Properties; Temperature; Trastuzumab	2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Anti-cancer drugs, 2016, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2016
Glucose regulated protein 78 (GRP78) inhibits apoptosis and attentinutes chemosensitivity of gemcitabine in breast cancer cell via AKT/mitochondrial apoptotic pathway. Biochemical and biophysical research communications, 2016, 06-03, Volume: 474, Issue:3 Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Gemcitabine; Heat-Shock Proteins; Humans; MCF-7 Cells; Mitochondria; Proto-Oncogene Proteins c-akt; Signal Transduction	2016
Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. International journal of nanomedicine, 2016, Volume: 11 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Half-Life; Humans; Hyaluronic Acid; Liposomes; MCF-7 Cells; Mice; Mice, Nude; Neoplastic Stem Cells; Xenograft Model Antitumor Assays	2016
Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application. Oncotarget, 2016, Jul-12, Volume: 7, Issue:28 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Magnetite Nanoparticles; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays	2016
GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Chemotherapy, 2017, Volume: 62, Issue:1 Topics: Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome	2017
Gemcitabine Induced Cutaneous Collagenous Vasculopathy in a Breast Cancer Patient. The breast journal, 2016, Volume: 22, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Skin Diseases, Vascular; Telangiectasis	2016
Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy. Oncotarget, 2016, 08-23, Volume: 7, Issue:34 Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; HEK293 Cells; Humans; Iodine Radioisotopes; Mice, Nude; Symporters; Transfection; Tumor Burden; Xenograft Model Antitumor Assays	2016
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature. Journal of the Egyptian National Cancer Institute, 2016, Volume: 28, Issue:4 Topics: Adult; Breast Neoplasms; Carboplatin; Carcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Medicine	2016
Inhibition of ERα/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. Oncotarget, 2016, Jul-26, Volume: 7, Issue:30 Topics: Antimetabolites, Antineoplastic; Autophagy; Beclin-1; Breast Neoplasms; Cytoprotection; Deoxycytidine; Estrogen Receptor alpha; Female; Flavonoids; Gemcitabine; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Prohibitins; RNA Interference; RNA, Small Interfering; Sequestosome-1 Protein; Signal Transduction	2016
Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells. Oncotarget, 2016, Sep-13, Volume: 7, Issue:37 Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Humans; Methylation; MicroRNAs; Promoter Regions, Genetic; RNA, Long Noncoding	2016
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer. European journal of cancer (Oxford, England : 1990), 2016, Volume: 66 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden	2016
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study. Medicine, 2016, Volume: 95, Issue:44 Topics: Aged; Antimetabolites, Antineoplastic; Brachytherapy; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies	2016
Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents. International journal of oncology, 2017, Volume: 50, Issue:1 Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Cysteine Endopeptidases; Deoxycytidine; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Enbucrilate; Etoposide; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Ubiquitin; Ubiquitin-Conjugating Enzymes; Vincristine	2017
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells. Molecular cancer therapeutics, 2017, Volume: 16, Issue:4 Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Osteosarcoma; Ovarian Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays	2017
The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines. International journal of cancer, 2008, Nov-15, Volume: 123, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Prostatic Neoplasms; Transplantation, Heterologous	2008
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer cell, 2008, Sep-09, Volume: 14, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Therapy, Combination; Endothelial Cells; Female; Gemcitabine; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Stem Cells; Tumor Burden; Vascular Endothelial Growth Factor A	2008
Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Molecular cancer therapeutics, 2008, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Breast Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Drug Carriers; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Humans; Mice; Nanogels; Nucleosides; Polyethylene Glycols; Polyethyleneimine; Polymers; Polyphosphates	2008
Adrenal metastasis of breast cancer with involvement of the inferior vena cava. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:11 Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Mastectomy, Radical; Neoplasm Invasiveness; Radiography; Radiotherapy, Adjuvant; Renal Veins; Vena Cava, Inferior; Venous Thrombosis	2008
Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy, 2009, Volume: 55, Issue:3 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids	2009
[Effects of magnetic gemcitabine stealth nano-liposomes on the characteristics of breast cancer cell line MCF-7]. Yao xue xue bao = Acta pharmaceutica Sinica, 2009, Volume: 44, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Magnetics; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Tissue Distribution; Tumor Burden	2009
The "win-win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy. World journal of surgical oncology, 2009, May-05, Volume: 7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Trastuzumab	2009
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer. Radiation oncology (London, England), 2009, Jul-11, Volume: 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome	2009
Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer letters, 2010, Apr-01, Volume: 290, Issue:1 Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Copper; Deoxycytidine; Disulfiram; Drug Resistance, Neoplasm; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Fluorouracil; Gemcitabine; Humans; NF-kappa B; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tumor Suppressor Proteins	2010
The effects of Gemcitabine and Vinorelbine on inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) distribution of MCF-7 breast cancer cells. Acta histochemica, 2011, Volume: 113, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Vinblastine; Vinorelbine	2011
What does similarity mean in clinical trials? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids	2009
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer investigation, 2010, Volume: 28, Issue:2 Topics: Adult; Aged; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins	2010
Memoirs of differential radiation doses: Gemcitabine induced radiation recall. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Mastectomy; Radiodermatitis; Radiotherapy; Radiotherapy Dosage	2010
Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast (Edinburgh, Scotland), 2010, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome	2010
Toxicities of gemcitabine in patients with severe hepatic dysfunction. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:4 Topics: Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Liver Diseases; Male; Neoplasms; Pancreatic Neoplasms; Platelet Count; Retrospective Studies	2010
Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells. BMC cancer, 2010, Apr-12, Volume: 10 Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, SCID; Microbial Sensitivity Tests; Microtubules; Molecular Chaperones; Paclitaxel; Transfection; Tubulin; Tubulin Modulators; Vinblastine; Vinorelbine	2010
The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. Journal of experimental therapeutics & oncology, 2010, Volume: 8, Issue:3 Topics: Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Membrane Transport Proteins; RNA, Messenger	2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer research, 2010, Oct-15, Volume: 70, Issue:20 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Colony-Forming Units Assay; Deoxycytidine; DNA Repair; Drug Synergism; Female; Gemcitabine; Histones; Humans; Rad51 Recombinase	2010
Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:3 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Salvage Therapy; Thrombotic Microangiopathies	2011
Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion. Asian Pacific journal of cancer prevention : APJCP, 2010, Volume: 11, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Prognosis	2010
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. International journal of cancer, 2011, Mar-15, Volume: 128, Issue:6 Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, Western; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lenalidomide; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Thalidomide; Tumor Cells, Cultured	2011
Simultaneous breast and ovarian metastasis from gallbladder carcinoma. Hepatobiliary & pancreatic diseases international : HBPD INT, 2010, Volume: 9, Issue:5 Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Mastectomy; Middle Aged; Ovarian Neoplasms; Ovariectomy; Salpingectomy	2010
Cytotoxic effects of new trans-2,4-diaryl-r-3-methyl-1,2,3,4-tetrahydroquinolines and their interaction with antitumoral drugs gemcitabine and paclitaxel on cellular lines of human breast cancer. Chemico-biological interactions, 2011, Feb-01, Volume: 189, Issue:3 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Quinolines	2011
Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Bioorganic & medicinal chemistry, 2011, Jan-01, Volume: 19, Issue:1 Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Genes, erbB-2; Humans; Immunoconjugates	2011
Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. AJR. American journal of roentgenology, 2011, Volume: 196, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoembolization, Therapeutic; Combined Modality Therapy; Contrast Media; Deoxycytidine; Female; Gadolinium DTPA; Gemcitabine; Humans; Laser Therapy; Liver Neoplasms; Magnetic Resonance Imaging, Interventional; Middle Aged; Mitomycin; Prospective Studies; Radiography, Interventional; Retreatment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome	2011
Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome	2011
Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience. Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate	2011
Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells. Molecular cancer therapeutics, 2011, Volume: 10, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Deoxycytidine; Female; Gemcitabine; Gene Silencing; GTP-Binding Proteins; Humans; Mice; Mice, SCID; Microtubules; Molecular Chaperones; Protein Transport; Tubulin; Xenograft Model Antitumor Assays	2011
Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Salvage Therapy; Statistics, Nonparametric; Treatment Outcome	2012
Off-label use of oxaliplatin in patients with metastatic breast cancer. Anticancer research, 2011, Volume: 31, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Off-Label Use; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome	2011
In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system. Journal of nanoscience and nanotechnology, 2011, Volume: 11, Issue:4 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Materials Testing; Nanocapsules; Rats; Treatment Outcome	2011
A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases. Oncology research, 2011, Volume: 19, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Deoxycytidine; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Female; Gemcitabine; Humans; Injections, Intralesional; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Technetium; Tumor Cells, Cultured	2011
Taxane doublets for metastatic breast cancer: do we need another cytotoxic pair or another approach? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Dec-20, Volume: 29, Issue:36 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Receptor, ErbB-2; Taxoids	2011
Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases. International journal of pharmaceutics, 2012, Jan-17, Volume: 422, Issue:1-2 Topics: 1,2-Dipalmitoylphosphatidylcholine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cholesterol; Colloids; Deoxycytidine; Dose-Response Relationship, Drug; Drug Compounding; Fatty Acids, Monounsaturated; Female; Gemcitabine; Humans; Kinetics; Lipids; Liposomes; Particle Size; Phosphatidylethanolamines; Phosphatidylglycerols; Polyethylene Glycols; Quaternary Ammonium Compounds; Selective Estrogen Receptor Modulators; Solubility; Tamoxifen; Technology, Pharmaceutical	2012
Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine. The AAPS journal, 2012, Volume: 14, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Imidazoles; Models, Biological; Pyrazines; Receptor, IGF Type 1; Signal Transduction; Somatomedins	2012
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma, 2012, Volume: 59, Issue:1 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Taxoids; Thrombocytopenia	2012
Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway. Acta histochemica, 2012, Volume: 114, Issue:7 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Janus Kinases; Signal Transduction; STAT Transcription Factors	2012
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study. Current medical research and opinion, 2012, Volume: 28, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab	2012
Cutaneous presentation of a distant metastasis of malignant phyllodes tumor. International journal of dermatology, 2012, Volume: 51, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Phyllodes Tumor; Skin Neoplasms; Treatment Outcome	2012
Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. International journal of clinical oncology, 2013, Volume: 18, Issue:2 Topics: Aged; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis	2013
Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines. Gene, 2012, May-01, Volume: 498, Issue:2 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; Electrophoresis, Gel, Pulsed-Field; Epithelial Cells; Female; Gemcitabine; Humans; Mutation; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53	2012
ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. International journal of oncology, 2012, Volume: 41, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Paclitaxel; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4	2012
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss medical weekly, 2012, Volume: 142 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine	2012
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer biology & therapy, 2012, Volume: 13, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Erythema; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Polyethylene Glycols; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome	2012
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer discovery, 2012, Volume: 2, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Checkpoint Kinase 1; Cyclins; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Mitosis; Nuclear Proteins; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Quinolines; S Phase; Thiazoles; Thiophenes; Transcription Factors; Tumor Burden; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays	2012
Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012, Volume: 82, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Gemcitabine; Humans; Hydrazines; Liposomes; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Nylons; Xenograft Model Antitumor Assays	2012
Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012, Volume: 82, Issue:2 Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Survival; Deoxycytidine; Drug Stability; Female; Gemcitabine; Half-Life; Humans; Linoleic Acid; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nucleoside Transport Proteins; Prodrugs; Rats; Rats, Sprague-Dawley	2012
Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy. Cancer letters, 2013, Jul-01, Volume: 334, Issue:2 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Random Allocation; Terpenes; Xenograft Model Antitumor Assays	2013
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. International journal of cancer, 2013, Jun-15, Volume: 132, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Mice; Taxoids; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays	2013
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid	2012
[A case of recurrent breast cancer in which gemcitabine-docetaxel therapy was successful for a long period]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Recurrence; Taxoids; Time Factors	2012
Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation. Molecular pharmaceutics, 2013, Feb-04, Volume: 10, Issue:2 Topics: Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Deoxycytidine; Eukaryotic Initiation Factor-4E; Gemcitabine; Guanosine Monophosphate; Humans; Lung Neoplasms; Models, Chemical; Proteasome Endopeptidase Complex; Spectrometry, Mass, Electrospray Ionization	2013
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2002, Volume: 22, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms	2002
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ]. Bulletin du cancer, 2002, Volume: 89 Spec No Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine	2002
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:3 Topics: Breast Neoplasms; Colonic Neoplasms; Colony-Forming Units Assay; Colorimetry; Combined Modality Therapy; Deoxycytidine; Fluorescent Dyes; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Rhodamines; Sensitivity and Specificity; Tumor Cells, Cultured	2003
Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors. Cancer investigation, 2003, Volume: 21, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Mitoguazone; Rats; Survival Analysis; Tumor Cells, Cultured	2003
Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bryostatins; Cell Survival; Cytosol; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gemcitabine; Humans; Isoenzymes; Lactones; Macrolides; Protein Kinase C; Tumor Cells, Cultured	2003
Fatal cholestatic liver failure associated with gemcitabine therapy. Digestive diseases and sciences, 2003, Volume: 48, Issue:9 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Cholestasis, Intrahepatic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver; Liver Failure, Acute; Liver Neoplasms; Middle Aged; Necrosis	2003
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular cancer therapeutics, 2003, Volume: 2, Issue:10 Topics: Annexin A5; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; Detergents; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Epothilones; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Multienzyme Complexes; Phosphorylation; Precipitin Tests; Proteasome Endopeptidase Complex; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sepharose; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab	2003
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination]. Krankenpflege Journal, 2003, Volume: 41, Issue:7-9 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids	2003
New perspectives with antimetabolites in the management of breast cancer. Clinical breast cancer, 2004, Volume: 4 Suppl 3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans	2004
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Colonic Neoplasms; Deoxycytidine; Dexamethasone; Drug Synergism; Gemcitabine; Glioma; Half-Life; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Transplantation, Heterologous	2004
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. Journal of the National Cancer Institute, 2004, May-19, Volume: 96, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine	2004
Promising combination therapies with gemcitabine. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Synergism; Gemcitabine; Histones; Humans; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Stem Cell Assay	2004
Setting the record straight: activity of gemcitabine monotherapy for breast cancer. Oncology, 2004, Volume: 66, Issue:4 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Treatment Outcome	2004
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone marrow transplantation, 2004, Volume: 34, Issue:5 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome	2004
Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-01, Volume: 22, Issue:21 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypersensitivity, Delayed; Methotrexate; Plant Extracts; Plant Proteins	2004
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC cancer, 2004, Nov-23, Volume: 4 Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms	2004
Acetaminophen and DMSO modulate growth and gemcitabine cytotoxicity in FM3A breast cancer cells in vitro. Neoplasma, 2004, Volume: 51, Issue:6 Topics: Acetaminophen; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Breast Neoplasms; Cell Division; Cyclooxygenase Inhibitors; Deoxycytidine; Dimethyl Sulfoxide; Gemcitabine; Humans; Ribonucleotide Reductases; S Phase; Time Factors; Tumor Cells, Cultured	2004
Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer. Breast cancer research and treatment, 2005, Volume: 89, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Quality of Life; Vinblastine; Vinorelbine	2005
[A new therapy standard in metastatic breast cancer--gemzar/paclitaxel. Longer survival by optimized combination therapy]. Krankenpflege Journal, 2004, Volume: 42, Issue:7-10 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate	2004
Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. International journal of surgical pathology, 2005, Volume: 13, Issue:1 Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Breast Neoplasms; Cytoplasmic Vesicles; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Microscopy, Electron, Transmission; Sarcoma; Soft Tissue Neoplasms; Transcription Factors; Treatment Outcome; Xanthomatosis	2005
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast cancer research and treatment, 2005, Volume: 90, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Flavonoids; Gemcitabine; Humans; Piperidines	2005
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine]. Voprosy onkologii, 2005, Volume: 51, Issue:1 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids	2005
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Molecular cancer therapeutics, 2005, Volume: 4, Issue:8 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Protein Subunits; Ribonucleotide Reductases; Up-Regulation	2005
Importance of rational pre-clinical development: gemcitabine comes of age. Cancer biology & therapy, 2005, Volume: 4, Issue:8 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Mice; Xenograft Model Antitumor Assays	2005
Gemcitabine-induced respiratory failure associated with elevated erythrocyte sedimentation rate (ESR). Respiratory medicine, 2006, Volume: 100, Issue:4 Topics: Adrenal Cortex Hormones; Antimetabolites, Antineoplastic; Blood Sedimentation; Breast Neoplasms; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Respiratory Distress Syndrome; Treatment Outcome	2006
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer biology & therapy, 2005, Volume: 4, Issue:8 Topics: Animals; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Paclitaxel; Taxoids; Xenograft Model Antitumor Assays	2005
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clinical breast cancer, 2005, Volume: 6, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel	2005
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha	2006
Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast cancer research and treatment, 2006, Volume: 96, Issue:3 Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bioreactors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lactic Acid	2006
Targeting oncogenes to improve breast cancer chemotherapy. Cancer research, 2006, Apr-15, Volume: 66, Issue:8 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; Gene Expression; Genes, myc; Humans; Molecular Sequence Data; Oligonucleotides; Transcription, Genetic	2006
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Apr-20, Volume: 24, Issue:12 Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Treatment Outcome	2006
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology, 2006, Volume: 70, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid	2006
Pulmonary toxicity in patients treated with gemcitabine and a combination of gemcitabine and a taxane: investigation of a signal using postmarketing data. British journal of cancer, 2006, Jun-05, Volume: 94, Issue:11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Taxoids	2006
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenetics and genomics, 2006, Volume: 16, Issue:6 Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Stomach Neoplasms; Tumor Suppressor Proteins	2006
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients. Journal of experimental & clinical cancer research : CR, 2006, Volume: 25, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome	2006
Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure	2006
Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Molecular pharmacology, 2006, Volume: 70, Issue:3 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Mammary Glands, Animal; Mice; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured	2006
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer biology & therapy, 2006, Volume: 5, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; I-kappa B Kinase; Mitosis; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured	2006
Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast cancer research and treatment, 2007, Volume: 102, Issue:2 Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; NF-kappa B; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Signal Transduction; Tissue Array Analysis; Tumor Cells, Cultured	2007
[Apoptosis of breast cancer cell line MCF-7 cells induced by gemcitabine and radiation]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2006, Volume: 31, Issue:5 Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Radiation; Radiation-Sensitizing Agents; Tumor Cells, Cultured	2006
Treatment options for patients with pretreated metastatic breast cancer. The Lancet. Oncology, 2007, Volume: 8, Issue:3 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Retreatment; Taxoids; Vinblastine; Vinorelbine	2007
A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respiratory research, 2007, Jun-14, Volume: 8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Proliferation; Cells, Cultured; Deoxycytidine; DNA; Drug Resistance; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Tissue Survival; Treatment Outcome; Vinblastine; Vinorelbine	2007
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. The oncologist, 2007, Volume: 12, Issue:6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Haplotypes; Humans; Middle Aged; Neutropenia; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Tumor Suppressor Proteins	2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome	2007
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer research, 2007, Aug-01, Volume: 67, Issue:15 Topics: Adenoviridae; Animals; Antigens, CD; Antigens, Differentiation; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; CTLA-4 Antigen; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Docetaxel; Doxorubicin; Female; Flow Cytometry; Galactosylceramides; Gemcitabine; Genetic Vectors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immunization; Immunotherapy; Mice; Myeloid Cells; Peptide Fragments; Receptor, ErbB-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Transfection; Vaccines, DNA	2007
[Consideration of preventive free-flowing IV infusion method for vinorelbine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Phlebitis; Trastuzumab; Vinblastine; Vinorelbine	2007
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2007, Volume: 61, Issue:9 Topics: Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genes, erbB-2; Humans; Paclitaxel; Retrospective Studies	2007
Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. European radiology, 2008, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Palliative Care; Treatment Outcome	2008
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling. International journal of oncology, 2008, Volume: 32, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Poly(ADP-ribose) Polymerases	2008
Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology, 2007, Volume: 72, Issue:5-6 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Retrospective Studies; Taxoids	2007
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Trastuzumab; Treatment Failure	2008
[A case of HER2-positive metastatic breast cancer responding to trastuzumab plus gemcitabine combination therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoembryonic Antigen; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiography; Receptor, ErbB-2; Tomography Scanners, X-Ray Computed; Trastuzumab	2008
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 11 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms	1995
Gemcitabine in advanced breast cancer. Anti-cancer drugs, 1995, Volume: 6 Suppl 6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Quality of Life; United States	1995
Docetaxel and gemcitabine released for cancer chemotherapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Jul-15, Volume: 53, Issue:14 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration	1996
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Investigational new drugs, 1996, Volume: 14, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Molecular Structure; Pancreatic Neoplasms; Transplantation, Heterologous; Treatment Outcome	1996
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team. Investigational new drugs, 1996, Volume: 14, Issue:3 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Stem Cell Assay	1996
[Oncology--a common language, new perspectives. Lilly Oncology Global Medical Conference, Indianapolis, 1996]. Pneumologie (Stuttgart, Germany), 1996, Volume: 50, Issue:9 Suppl Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Medical Oncology; Pancreatic Neoplasms; Urinary Bladder Neoplasms	1996
Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:14 Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Treatment Failure	1997
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anti-cancer drugs, 1998, Volume: 9, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine	1998
Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. International journal of cancer, 1999, Jan-29, Volume: 80, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Tumor Stem Cell Assay	1999
Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:3 Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Radiodermatitis	2000
Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome. Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4 Topics: Antigens, Polyomavirus Transforming; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Breast Neoplasms; Cloning, Molecular; Cytarabine; Deoxycytidine; DNA Polymerase I; DNA Polymerase III; DNA, Neoplasm; Gemcitabine; Humans; Replicon; Tumor Cells, Cultured	2000
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics, Nonparametric; Survival Analysis; Treatment Outcome	2000
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration; international review of thoracic diseases, 2000, Volume: 67, Issue:6 Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Paclitaxel; Pulmonary Edema; Radiography; Taxoids	2000
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. Anti-cancer drugs, 2001, Volume: 12, Issue:3 Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Hematologic Tests; Humans; Male; Middle Aged; Myeloid Cells	2001
Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer. Investigational new drugs, 2001, Volume: 19, Issue:1 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms	2001
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anti-cancer drugs, 2001, Volume: 12, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine	2001
Resistance to topoisomerase poisons due to loss of DNA mismatch repair. International journal of cancer, 2001, Aug-15, Volume: 93, Issue:4 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	2001
Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8 Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Survival; Deoxyadenine Nucleotides; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Genotype; Humans; Mutation; Radiation-Sensitizing Agents; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2001
Gemcitabine active in patients with metastatic breast cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:7 Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Multicenter Studies as Topic; Treatment Outcome	2001
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast cancer research and treatment, 2001, Volume: 67, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Epirubicin; Female; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine	2001
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. International journal of cancer, 2002, Feb-01, Volume: 97, Issue:4 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; DNA Damage; DNA Replication; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; G1 Phase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, Dominant; Genes, p53; Humans; Neoplasm Proteins; Neoplastic Stem Cells; Phenotype; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; S Phase; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2002
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clinical breast cancer, 2000, Volume: 1, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome	2000
Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines. Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Clinical Trials as Topic; Dactinomycin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Time Factors; Tumor Cells, Cultured	2002